

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problems Mailbox.**

AR

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>A61K 31/35, 31/38, 31/415, C07D</b> <b>311/60, 335/06, 403/04</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 96/40110</b> <b>(43) International Publication Date:</b> 19 December 1996 (19.12.96)
<b>(21) International Application Number:</b> PCT/US96/08312 <b>(22) International Filing Date:</b> 3 June 1996 (03.06.96) <b>(30) Priority Data:</b> 479,876                      7 June 1995 (07.06.95)                      US <b>(71) Applicant:</b> SUGEN, INC. [US/US]; 515 Galveston Drive, Redwood City, CA 94063 (US). <b>(72) Inventors:</b> TANG, Peng, Cho; 827 Camino Ricardo, Moraga, CA 94556 (US). MCMAHON, Gerald; 1800 Schultz Road, Kenwood, CA 95452 (US). <b>(74) Agents:</b> CORUZZI, Laura, A. et al.; Pennie & Edmonds, 1155 Avenue of the Americas, New York, NY 10036 (US).		<b>(81) Designated States:</b> AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IL, IS, JP, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> NOVEL BENZOPYRAN COMPOUNDS AND METHODS FOR THEIR USE <b>(57) Abstract</b> <p>The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**NOVEL BENZOPYRAN COMPOUNDS  
AND METHODS FOR THEIR USE**

**1. INTRODUCTION**

The present invention relates to novel compounds  
5 capable of modulating, regulating and/or inhibiting  
tyrosine kinase signal transduction and methods  
thereof. The present invention is also directed to  
novel compounds and methods related to tyrosine  
kinases, whether of the receptor or non-receptor  
10 class, for the prevention and/or treatment of  
disorders related to abnormal cell differentiation,  
proliferation and survival.

**2. BACKGROUND OF THE INVENTION**

15 Protein tyrosine kinases (PTKs) comprise a large  
and diverse class of proteins having enzymatic  
activity. The PTKs play an important role in the  
control of cell growth and differentiation (for  
review, see Schlessinger & Ullrich, 1992, *Neuron*  
20 9:383-391).

For example, receptor tyrosine kinase mediated  
signal transduction is initiated by extracellular  
interaction with a specific growth factor (ligand),  
followed by receptor dimerization, transient  
25 stimulation of the intrinsic protein tyrosine kinase  
activity and phosphorylation. Binding sites are  
thereby created for intracellular signal transduction  
molecules and lead to the formation of complexes with  
a spectrum of cytoplasmic signalling molecules that  
30 facilitate the appropriate cellular response. (E.g.,  
cell division, metabolic effects to the extracellular  
microenvironment) See, Schlessinger and Ullrich, 1992,  
*Neuron* 9:1-20.

With respect to receptor tyrosine kinases, it has  
35 been shown also that tyrosine phosphorylation sites  
function as high-affinity binding sites for SH2 (*src*

homology) domains of signaling molecules. Fantl et al., 1992, *Cell* 69:413-423; Songyang et al., 1994, *Mol. Cell. Biol.* 14:2777-2785); Songyang et al., 1993, *Cell* 72:767-778; and Koch et al., 1991, *Science* 252:668-678. Several intracellular substrate proteins that associate with receptor tyrosine kinases (RTKs) have been identified. They may be divided into two principal groups: (1) substrates which have a catalytic domain; and (2) substrates which lack such domain but serve as adapters and associate with catalytically active molecules. Songyang et al., 1993, *Cell* 72:767-778. The specificity of the interactions between receptors or proteins and SH2 domains of their substrates is determined by the amino acid residues immediately surrounding the phosphorylated tyrosine residue. Differences in the binding affinities between SH2 domains and the amino acid sequences surrounding the phosphotyrosine residues on particular receptors are consistent with the observed differences in their substrate phosphorylation profiles. Songyang et al., 1993, *Cell* 72:767-778. These observations suggest that the function of each receptor tyrosine kinase is determined not only by its pattern of expression and ligand availability but also by the array of downstream signal transduction pathways that are activated by a particular receptor. Thus, phosphorylation provides an important regulatory step which determines the selectivity of signaling pathways recruited by specific growth factor receptors, as well as differentiation factor receptors.

Aberrant expression or mutations in the PTKs have been shown to lead to either uncontrolled cell proliferation (e.g. malignant tumor growth) or to defects in key developmental processes. Consequently, the biomedical community has expended significant resources to discover the specific biological role of

members of the PTK family, their function in differentiation processes, their involvement in tumorigenesis and in other diseases, the biochemical mechanisms underlying their signal transduction pathways activated upon ligand stimulation and the development of novel drugs.

5 Tyrosine kinases can be of the receptor-type (having extracellular, transmembrane and intracellular domains) or the non-receptor type (being wholly intracellular).

10 *Receptor Tyrosine Kinases.* The RTKs comprise a large family of transmembrane receptors with diverse biological activities. The intrinsic function of RTKs is activated upon ligand binding, which results in phosphorylation of the receptor and multiple cellular substrates, and subsequently in a variety of cellular  
15 responses. Ullrich & Schlessinger, 1990, *Cell* 61:203-212.

At present, at least nineteen (19) distinct RTK subfamilies have been identified. One RTK subfamily, designated the HER subfamily, is believed to be  
20 comprised of EGFR, HER2, HER3 and HER4. Ligands to the Her subfamily of receptors include epithelial growth factor (EGF), TGF- $\alpha$ , amphiregulin, HB-EGF, betacellulin and heregulin.

25 A second family of RTKs, designated the insulin subfamily, is comprised of the INS-R, the IGF-1R and the IR-R. A third family, the "PDGF" subfamily includes the PDGF  $\alpha$  and  $\beta$  receptors, CSF1R, c-kit and FLK-II. Another subfamily of RTKs, identified as the  
30 FLK family, is believed to be comprised of the Kinase insert Domain-Receptor fetal liver kinase-1 (KDR/FLK-1), the fetal liver kinase 4 (FLK-4) and the fms-like tyrosine kinase 1 (flt-1). Each of these receptors was initially believed to be receptors for  
35 hematopoietic growth factors. Two other subfamilies of RTKs have been designated as the FGF receptor

family (FGFR1, FGFR2, FGFR3 and FGFR4) and the Met subfamily (c-met and Ron).

Because of the similarities between the PDGF and FLK subfamilies, the two subfamilies are often considered together. The known RTK subfamilies are identified in Plowman et al., 1994, *DN&P* 7(6):334-339, which is incorporated herein by reference.

*The Non-Receptor Tyrosine Kinases.* The non-receptor tyrosine kinases represent a collection of cellular enzymes which lack extracellular and transmembrane sequences. At present, over twenty-four individual non-receptor tyrosine kinases, comprising eleven (11) subfamilies (Src, Frk, Btk, Csk, Abl, Zap70, Fes/Fps, Fak, Jak, Ack and LIMK) have been identified. At present, the Src subfamily of non-receptor tyrosine kinases is comprised of the largest number of PTKs and include Src, Yes, Fyn, Lyn, Lck, Blk, Hck, Fgr and Yrk. The Src subfamily of enzymes has been linked to oncogenesis. A more detailed discussion of non-receptor tyrosine kinases is provided in Bolen, 1993, *Oncogene* 8:2025-2031, which is incorporated herein by reference.

Many of the tyrosine kinases, whether an RTK or non-receptor tyrosine kinase, have been found to be involved in cellular signaling pathways leading to cellular signal assays signalling pathways leading to pathogenic conditions, including cancer, psoriasis and hyper immune response.

*Development Of Compounds To Modulate The PTKs.* In view of the surmised importance of PTKs to the control, regulation and modulation of cell proliferation the diseases and disorders associated with abnormal cell proliferation, many attempts have been made to identify receptor and non-receptor tyrosine kinase "inhibitors" using a variety of approaches, including the use of mutant ligands (U.S. Application No. 4,966,849), soluble receptors and

antibodies (Application No. WO 94/10202; Kendall & Thomas, 1994, *Proc. Nat'l Acad. Sci* 90:10705-09; Kim, et al., 1993, *Nature* 362:841-844), RNA ligands (Jellinek, et al., *Biochemistry* 33:10450-56); Takano, et al., 1993, *Mol. Bio. Cell* 4:358A; Kinsella, et al., 1992, *Exp. Cell Res.* 199:56-62; Wright, et al., 1992, *J. Cellular Phys.* 152:448-57) and tyrosine kinase inhibitors (WO 94/03427; WO 92/21660; WO 91/15495; WO 94/14808; U.S. Patent No. 5,330,992; Mariani, et al., 1994, *Proc. Am. Assoc. Cancer Res.* 35:2268).

More recently, attempts have been made to identify small molecules which act as tyrosine kinase inhibitors. For example, bis monocyclic, bicyclic or heterocyclic aryl compounds (PCT WO 92/20642), vinylene-azaindole derivatives (PCT WO 94/14808) and 1-cyclopropyl-4-pyridyl-quinolones (U.S. Patent No. 5,330,992) have been described generally as tyrosine kinase inhibitors. Styryl compounds (U.S. Patent No. 5,217,999), styryl-substituted pyridyl compounds (U.S. Patent No. 5,302,606), certain quinazoline derivatives (EP Application No. 0 566 266 A1), seleoindoles and selenides (PCT WO 94/03427), tricyclic polyhydroxylic compounds (PCT WO 92/21660) and benzylphosphonic acid compounds (PCT WO 91/15495) have been described as compounds for use as tyrosine kinase inhibitors for use in the treatment of cancer.


The identification of effective small compounds which specifically inhibit tyrosine signal transduction by modulating the activity of receptor and non-receptor tyrosine kinases to regulate and modulate abnormal or inappropriate cell proliferation is therefore desirable and the object of this invention.

### 3. SUMMARY OF THE INVENTION

The present invention relates to organic molecules capable of modulating, regulating and/or



inhibiting cell proliferation by affecting tyrosine kinase signal transduction. Specifically, the compounds of the present invention have the formulae:



10

wherein:

X is O or S;

Q is an aryl (either mono- or bicyclic) optionally substituted with one or more R<sup>2</sup>;

n is 1, 2, 3 or 4;

15

R<sup>1</sup> is cyano, NO<sub>2</sub>, C(O)NHR<sup>2</sup>, S(O)<sub>2</sub>R<sup>2</sup> or S(O)<sub>2</sub>NHR<sup>2</sup>;

and

R<sup>2</sup> is H, halo, trihalomethyl, alkyl, thioalkyl, hydroxy, alkoxy, nitro, cyano, sulfonyl, amide, carboxyl, sulfonamide or amino.

20

Preferably, the compounds of the present invention have the formulae:



30

wherein R<sub>2</sub> and Q are as follows:

35

R <sub>2</sub>	Q
6,8-dichloro	4-fluorophenyl
8-methoxy	4-fluorophenyl
6-chloro	2,4-dichlorophenyl

	6-chloro	4-(methylmercapto)phenyl
	6-chloro	4-(methylmercapto)phenyl
	6-chloro	4-phenoxyphenyl
5	H	4-isopropylphenyl
	benzo	4-chlorophenyl
	H	thien-2-yl
	H	2-methoxyphenyl
	6-bromo	2-methoxyphenyl
10	H	benzofuran-2-yl
	6-chloro	2-cyanophenyl
	8-methoxy	2-nitrothien-4-yl
	8-methoxy	4-hydroxy-3-methoxyphenyl
15	8-methoxy	1-phenylpyrazol-3-yl
	8-methoxy	1-methylpyrazol-3-yl
	8-methoxy	5-bromo-2-methoxyphenyl
	8-methoxy	4-cyanophenyl
	8-methoxy	thien-3-yl
20	8-methoxy	3-(trifluoromethyl)phenyl
	8-methoxy	thien-2-yl
	6,8-dichloro	2-hydroxy-3-methoxy
	6,8-dichloro	4-chloro-1-methylpyrazol-3-yl
	6,8-dichloro	3-bromothien-5-yl
25	6,8-dichloro	2,5-dimethoxyphenyl
	6,8-dichloro	4-t-butylphenyl
	6,8-dichloro	4-acetamidophenyl
	6,8-dichloro	dioxolo[2,3-c]phenyl

30

The present invention is further directed to pharmaceutical compositions comprising a pharmaceutically effective amount of the above-described compounds and a pharmaceutically acceptable carrier or excipient. Such a composition is believed to modulate signal transduction by a tyrosine kinase,

35

either by inhibition of catalytic activity, affinity to ATP or ability to interact with a substrate.

More particularly, the compositions of the present invention may be included in methods for treating diseases comprising proliferation or metabolic disorders, for example cancer, fibrosis, psoriasis, atherosclerosis, arthritis, and other disorders related to abnormal vasculogenesis and/or angiogenesis, such as diabetic retinopathy.

### 3.1. Definitions

"Pharmaceutically acceptable acid addition salt" refers to those salts which retain the biological effectiveness and properties of the free bases and which are obtained by reaction with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.

"Alkyl" refers to a saturated aliphatic hydrocarbon, including straight-chain, branched-chain, and cyclic alkyl groups. Preferably, the alkyl group has 1 to 12 carbons. More preferably, it is a lower alkyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. Typical alkyl groups includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl and the like. The alkyl group may be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, =O, =S, NO<sub>2</sub>, N(CH<sub>3</sub>)<sub>2</sub>, amino, or SH.

"Alkenyl" refers to an unsaturated hydrocarbon group containing at least one carbon-carbon double bond, including straight-chain, branched-chain, and cyclic groups. Preferably, the alkenyl group has 1 to 12 carbons. More preferably it is a lower alkenyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkenyl group may be substituted or unsubstituted.

When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, =O, =S, NO<sub>2</sub>, halogen, N(CH<sub>3</sub>)<sub>2</sub>, amino, or SH. An "alkynyl" group refers to an unsaturated hydrocarbon group containing at least one carbon-carbon triple bond, including straight-chain, branched-chain, and cyclic groups.  
5 Preferably, the alkynyl group has 1 to 12 carbons. More preferably it is a lower alkynyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkynyl group may be substituted or unsubstituted. When substituted, the substituted group(s) is preferably,  
10 hydroxyl, cyano, alkoxy, =O, =S, NO<sub>2</sub>, halogen, N(CH<sub>3</sub>)<sub>2</sub>, amino, or SH.

"Alkoxy" refers to an "-Oalkyl" group, where "alkyl" is defined as described below.

15 "Aryl" refers to an aromatic group which has at least one ring having a conjugated pi electron system and includes carboxylic aryl, heterocyclic aryl and biaryl groups, all of which may be optionally substituted. Preferably, the aryl is a substituted or  
20 unsubstituted phenyl or pyridyl. Preferred aryl substituent(s) preferably phenyl or pyridyl are halogen, trihalomethyl, hydroxyl, SH OH, NO<sub>2</sub>, amine, thioether, cyano, alkoxy, alkyl, and amino groups.

25 "Alkylaryl" refers to an alkyl (as described above), covalently joined to an aryl group (as described above). Preferably, the alkyl is a lower alkyl.

"Carbocyclic aryl" refers to a group wherein the ring atoms on the aromatic ring are all carbon atoms. The carbon atoms are optionally substituted.  
30

"Heterocyclic aryl" refers to groups having from 1 to 3 heteroatoms as ring atoms in the aromatic ring and the remainder of the ring atoms are carbon atoms. Suitable heteroatoms include oxygen, sulfur, and  
35 nitrogen, and include furanyl, thienyl, pyridyl,

pyrrolyl, N-lower alkyl pyrrolo, pyrimidyl, pyrazinyl, imidazolyl and the like, all optionally substituted.

"Amide" refers to an  $-C(O)-NH-R$ , where R is either alkyl, aryl, alkylaryl or hydrogen.

5 "Thioamide" refers to  $-C(S)-NH-R$ , where R is either alkyl, aryl, alkylaryl or hydrogen.

"Amine" refers to a  $-N(R)R''$ , where R" and R"', is independently either hydrogen, alkyl, aryl, or alkylaryl, provided that R" and R"' are not both hydrogen.

10 "Thioether" refers to  $-S-R$ , where R is either alkyl, aryl, or alkylaryl.

"Sulfonyl" refers to  $-S(O)_2-R$ , where R is aryl,  $C(CN)=C$ -aryl,  $CH_2-CN$ , alkyaryl, NH-alkyl, NH-alkylaryl, or NH-aryl.

15

#### 4. DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to compounds capable of regulating and/or modulating tyrosine kinase signal transduction and more particularly receptor and non-receptor tyrosine kinase signal  
20 transduction.

Receptor tyrosine kinase mediated signal transduction is initiated by extracellular interaction with a specific growth factor (ligand), followed by  
25 receptor dimerization, transient stimulation of the intrinsic protein tyrosine kinase activity and phosphorylation. Binding sites are thereby created for intracellular signal transduction molecules and lead to the formation of complexes with a spectrum of  
30 cytoplasmic signalling molecules that facilitate the appropriate cellular response. (E.g., cell division, metabolic effects to the extracellular microenvironment) See, Schlessinger and Ullrich, 1992, Neuron 9:1-20.

35 It has been shown that tyrosine phosphorylation sites in growth factor receptors function as high-

affinity binding sites for SH2 (src homology) domains of signaling molecules. Fantl et al., 1992, *Cell* 69:413-423; Songyang et al., 1994, *Mol. Cell. Biol.* 14:2777-2785); Songyang et al., 1993, *Cell* 72:767-778; and Koch et al., 1991, *Science* 252:668-678.

5 Several intracellular substrate proteins that associate with receptor tyrosine kinases have been identified. They may be divided into two principal groups: (1) substrates which have a catalytic domain; and (2) substrates which lack such domain but serve as  
10 adapters and associate with catalytically active molecules. Songyang et al., 1993, *Cell* 72:767-778. The specificity of the interactions between receptors and SH2 domains of their substrates is determined by the amino acid residues immediately surrounding the  
15 phosphorylated tyrosine residue. Differences in the binding affinities between SH2 domains and the amino acid sequences surrounding the phosphotyrosine residues on particular receptors are consistent with the observed differences in their substrate  
20 phosphorylation profiles. Songyang et al., 1993, *Cell* 72:767-778. These observations suggest that the function of each receptor tyrosine kinase is determined not only by its pattern of expression and ligand availability but also by the array of  
25 downstream signal transduction pathways that are activated by a particular receptor. Thus, phosphorylation provides an important regulatory step which determines the selectivity of signaling pathways recruited by specific growth factor receptors, as well as differentiation factor receptors.


30 Tyrosine kinase signal transduction results in, among other responses, cell proliferation, differentiation and metabolism. Abnormal cell proliferation may result in a wide array of disorders and diseases, including the development of neoplasia  
35 such as carcinoma, sarcoma, leukemia, glioblastoma,

hemangioma, psoriasis, arteriosclerosis, arthritis and diabetic retinopathy (or other disorders related to uncontrolled angiogenesis and/or vasculogenesis).

This invention is therefore directed to compounds which regulate, modulate and/or inhibit disorders associated with abnormal cell proliferation by affecting the enzymatic activity of the RTKs and/or the non-receptor tyrosine kinases and interfering with the signal transduced such proteins. More particularly, the present invention is directed to compounds which regulate, modulate and/or inhibit the RTK and/or non-receptor tyrosine kinase mediated signal transduction pathways as a therapeutic approach to cure many kinds of solid tumors, including but not limited to carcinoma, sarcoma, leukemia, erythroblastoma, glioblastoma, meningioma, astrocytoma, melanoma and myoblastoma. Indications may include, but are not limited to brain cancers, bladder cancers, ovarian cancers, gastric cancers, pancreas cancers, colon cancers, blood cancers, lung cancers and bone cancers.

#### 4.1. The Compounds

The invention is generally directed to compounds and/or compositions comprising compounds having the formulae:



wherein:

$X$  is O or S;

$Q$  is an aryl (either mono- or bicyclic) optionally substituted with one or more  $R^2$ ;

n is 1, 2, 3 or 4;

R<sup>1</sup> is cyano, NO<sub>2</sub>, C(O)NHR<sup>2</sup>, S(O)<sub>2</sub>R<sup>2</sup> or S(O)<sub>2</sub>NHR<sup>2</sup>;


and

R<sup>2</sup> is H, halo, trihalomethyl, alkyl, thioalkyl, hydroxy, alkoxy, nitro, cyano, sulfonyl, amide, carboxyl, sulfonamide or amino.

5

Preferably, the compounds of the present invention have the formulae:

10



15

wherein R<sub>2</sub> and Q are as follows:

20

25

30

35

R <sub>2</sub>	Q
6,8-dichloro	4-fluorophenyl
8-methoxy	4-fluorophenyl
6-chloro	2,4-dichlorophenyl
6-chloro	4-(methylmercapto)phenyl
6-chloro	4-(methylmercapto)phenyl
6-chloro	4-phenoxyphenyl
H	4-isopropylphenyl
benzo	4-chlorophenyl
H	thien-2-yl
H	2-methoxyphenyl
6-bromo	2-methoxyphenyl
H	benzofuran-2-yl
6-chloro	2-cyanophenyl
8-methoxy	2-nitrothien-4-yl
8-methoxy	4-hydroxy-3-methoxyphenyl
8-methoxy	1-phenylpyrazol-3-yl
8-methoxy	1-methylpyrazol-3-yl



	8-methoxy	5-bromo-2-methoxyphenyl
	8-methoxy	4-cyanophenyl
	8-methoxy	thien-3-yl
	8-methoxy	3-(trifluoromethyl)phenyl
5	8-methoxy	thien-2-yl
	6,8-dichloro	2-hydroxy-3-methoxy
	6,8-dichloro	4-chloro-1-methylpyrazol-3-yl
	6,8-dichloro	3-bromothien-5-yl
10	6,8-dichloro	2,5-dimethoxyphenyl
	6,8-dichloro	4-t-butylphenyl
	6,8-dichloro	4-acetamidophenyl
	6,8-dichloro	dioxolo[2,3-c]phenyl

The chemical formulae referred herein may exhibit the phenomenon of tautomerism. As the formulae drawing within this specification can only represent one of the possible tautomeric forms, it should be understood that the invention encompasses any tautomeric form which possesses the ability to regulate and/or modulate cell proliferation and is not limited to any one tautomeric form utilized within the formulae drawing.

In addition to the above compounds and their pharmaceutically acceptable salts, the invention is further directed, where applicable, to solvated as well as unsolvated forms of the compounds (e.g. hydrated forms) having the ability to regulate and/or modulate cell proliferation.

The compounds described above may be prepared by any process known to be applicable to the preparation of chemically-related compounds. Suitable processes are illustrated by the following representative examples. Necessary starting materials may be obtained by standard procedures of organic chemistry.

35

An individual compound's relevant activity and efficiency as an agent to affect receptor tyrosine kinase mediated signal transduction may be determined using available techniques. Preferentially, a compound is subjected to a series of screens to determine the compound's ability to modulate, regulate and/or inhibit cell proliferation. These screens, in the order in which they are conducted, include biochemical assays, cell growth assays and *in vivo* experiments.

#### 4.2. Indications

Cell proliferative disorders which can be treated or further studied by the present invention include cancers, blood vessel proliferative disorders, fibrotic disorders, and mesangial cell proliferative disorders.

Blood vessel proliferation disorders refer to angiogenic and vasculogenic disorders generally resulting in abnormal proliferation of blood vessels. The formation and spreading of blood vessels, or vasculogenesis and angiogenesis, respectively, play important roles in a variety of physiological processes such as embryonic development, corpus luteum formation, wound healing and organ regeneration. They also play a pivotal role in cancer development. Other examples of blood vessel proliferation disorders include arthritis, where new capillary blood vessels invade the joint and destroy cartilage, and ocular diseases, like diabetic retinopathy, where new capillaries in the retina invade the vitreous, bleed and cause blindness. Conversely, disorders related to the shrinkage, contraction or closing of blood vessels, such as restenosis, are also implicated.

Fibrotic disorders refer to the abnormal formation of extracellular matrix. Examples of fibrotic disorders include hepatic cirrhosis and mesangial cell proliferative disorders. Hepatic

cirrhosis is characterized by the increase in extracellular matrix constituents resulting in the formation of a hepatic scar. Hepatic cirrhosis can cause diseases such as cirrhosis of the liver. An increased extracellular matrix resulting in a hepatic scar can also be caused by viral infection such as hepatitis. Lipocytes appear to play a major role in hepatic cirrhosis. Other fibrotic disorders implicated include atherosclerosis (see, below).

Mesangial cell proliferative disorders refer to disorders brought about by abnormal proliferation of mesangial cells. Mesangial proliferative disorders include various human renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, transplant rejection, and glomerulopathies. The PDGF-R has been implicated in the maintenance of mesangial cell proliferation. Floege et al., 1993, *Kidney International* 43S:47-54.

The cell proliferative disorders which are indications of the present invention are not necessarily independent. For example, fibrotic disorders may be related to, or overlap, with blood vessel proliferative disorders. For example, atherosclerosis results, in part, in the abnormal formation of fibrous tissue within blood vessels.

PTKs have been associated with such cell proliferative disorders. For example, some members of the RTK family have been associated with the development of cancer. Some of these receptors, like the EGFR (Tuzi et al., 1991, *Br. J. Cancer* 63:227-233; Torp et al., 1992, *APMIS* 100:713-719) HER2/neu (Slamon et al., 1989, *Science* 244:707-712) and the PDGF-R (Kumabe et al., 1992, *Oncogene* 7:627-633) are overexpressed in many tumors and/or persistently activated by autocrine loops. In fact, in the most common and severe cancers these receptor

overexpressions (Henriksen et al., 1992, *J. Neurol. Sci.* 111:119-133; Dickson et al., 1992, *Cancer Treatment Res.* 61:249-273; Kore et al., 1992, *J. Clin. Invest.* 90:1352-1360) and autocrine loops (Lee and Donoghue, 1992, *J. Cell. Biol.* 118:1057-1070; Kore et al., *supra*; Henrikson et al., *supra*) have been demonstrated. For example, the EGFR receptor has been associated with squamous cell carcinoma, astrocytoma, glioblastoma, head and neck cancer, lung cancer and bladder cancer. HER2 has been associated with breast, ovarian, gastric, lung, pancreas and bladder cancer. The PDGF-R has been associated with glioblastoma, lung, ovarian, melanoma and prostate. The RTK c-met has been generally associated with hepatocarcinogenesis and thus hepatocellular carcinoma. Additionally, c-met has been linked to malignant tumor formation. More specifically, the RTK c-met has been associated with, among other cancers, colorectal, thyroid, pancreatic and gastric carcinoma, leukemia and lymphoma. Additionally, over-expression of the c-met gene has been detected in patients with Hodgkins disease, Burkitts disease, and the lymphoma cell line.

The IGF-IR, in addition to being implicated in nutritional support and in type-II diabetes, has also been associated with several types of cancers. For example, IGF-I has been implicated as an autocrine growth stimulator for several tumor types, e.g. human breast cancer carcinoma cells (Arteaga et al., 1989, *J. Clin. Invest.* 84:1418-1423) and small lung tumor cells (Macauley et al., 1990, *Cancer Res.* 50:2511-2517). In addition, IGF-I, integrally involved in the normal growth and differentiation of the nervous system, appears to be an autocrine stimulator of human gliomas. Sandberg-Nordqvist et al., 1993, *Cancer Res.* 53:2475-2478. The importance of the IGF-IR and its ligands in cell proliferation is further supported by

the fact that many cell types in culture (fibroblasts, epithelial cells, smooth muscle cells, T-lymphocytes, myeloid cells, chondrocytes, osteoblasts, the stem cells of the bone marrow) are stimulated to grow by IGF-I. Goldring and Goldring, 1991, *Eukaryotic Gene Expression* 1:301-326. In a series of recent  
5 publications, Baserga even suggests that IGF-I-R plays a central role in the mechanisms of transformation and, as such, could be a preferred target for therapeutic interventions for a broad spectrum of human malignancies. Baserga, 1995, *Cancer Res.*  
10 55:249-252; Baserga, 1994, *Cell* 79:927-930; Coppola et al., 1994, *Mol. Cell. Biol.* 14:4588-4595 .

The association between abnormalities in RTKs and disease are not restricted to cancer, however. For  
15 example, RTKs have been associated with metabolic diseases like psoriasis, diabetes mellitus, wound healing, inflammation, and neurodegenerative diseases. For example, the EGF-R is indicated in corneal and dermal wound healing. Defects in the Insulin-R and  
20 the IGF-1R are indicated in type-II diabetes mellitus. A more complete correlation between specific RTKs and their therapeutic indications is set forth in Plowman et al., 1994, *DN&P* 7(6):334-339.

Not only receptor type tyrosine kinases, but also  
25 many cellular tyrosine kinases (CTKs) including src, abl, fps, yes, fyn, lyn, lck, blk, hck, fgr, yrk (reviewed by Bolen et al., 1992, *FASEB J.* 6:3403-3409) are involved in the proliferative and metabolic signal transduction and thus in indications of the present  
30 invention. For example, mutated src (v-src) has been demonstrated as an oncoprotein (pp60<sup>v-src</sup>) in chicken. Moreover, its cellular homolog, the proto-oncogene pp60<sup>c-src</sup> transmits oncogenic signals of many receptors. For example, overexpression of EGF-R or HER2/neu in  
35 tumors leads to the constitutive activation of

pp60<sup>c-src</sup>, which is characteristic for the malignant cell but absent from the normal cell. On the other hand, mice deficient for the expression of c-src exhibit an osteopetrotic phenotype, indicating a key participation of c-src in osteoclast function and a possible involvement in related disorders. Similarly, Zap 70 is implicated in T-cell signalling.

Finally, the identification of CTK modulating compounds to augment or even synergize with RTK aimed blockers is an aspect of the present invention.

Finally, both RTKs and non-receptor type kinases have been connected to hyperimmune disorders.

#### 4.3. Pharmaceutical Formulations And Routes Of Administration

The identified compounds can be administered to a human patient, by itself, or in pharmaceutical compositions where it is mixed with suitable carriers or excipient(s) at doses to treat or ameliorate a variety of disorders. A therapeutically effective dose further refers to that amount of the compound sufficient to result in amelioration of symptoms. Techniques for formulation and administration of the compounds of the instant application may be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, latest edition.

##### 4.3.1. Routes Of Administration.

Suitable routes of administration may, for example, include oral, rectal, transmucosal, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections.

Alternately, one may administer the compound in a local rather than systemic manner, for example, via injection of the compound directly into a solid tumor, often in a depot or sustained release formulation.

Furthermore, one may administer the drug in a targeted drug delivery system, for example, in a liposome coated with tumor-specific antibody. The liposomes will be targeted to and taken up selectively by the tumor.

#### 4.3.2. Composition/Formulation.

5           The pharmaceutical compositions of the present invention may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, 10           emulsifying, encapsulating, entrapping or lyophilizing processes.

          Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically 15           acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent 20           upon the route of administration chosen.

          For injection, the agents of the invention may be 20           formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants 25           appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

          For oral administration, the compounds can be formulated readily by combining the active compounds 30           with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be 35           treated. Pharmaceutical preparations for oral use can be obtained solid excipient, optionally grinding a

resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration.



For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or

dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle,  
5 e.g., sterile pyrogen-free water, before use.

The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.  
10

In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular  
15 injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.  
20

A pharmaceutical carrier for the hydrophobic compounds of the invention is a cosolvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. The cosolvent system may be the VPD co-solvent system.  
25 VPD is a solution of 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant polysorbate 80, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol. The VPD co-solvent system (VPD:5W) consists of VPD diluted 1:1 with a 5% dextrose in water  
30 solution. This co-solvent system dissolves hydrophobic compounds well, and itself produces low toxicity upon systemic administration. Naturally, the proportions of a co-solvent system may be varied considerably without destroying its solubility and  
35 toxicity characteristics. Furthermore, the identity

of the co-solvent components may be varied: for example, other low-toxicity nonpolar surfactants may be used instead of polysorbate 80; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g. polyvinyl pyrrolidone; and other sugars or polysaccharides may substitute for dextrose.

Alternatively, other delivery systems for hydrophobic pharmaceutical compounds may be employed. Liposomes and emulsions are well known examples of delivery vehicles or carriers for hydrophobic drugs. Certain organic solvents such as dimethylsulfoxide also may be employed, although usually at the cost of greater toxicity. Additionally, the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various of sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed.

The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.

Many of the PTK modulating compounds of the invention may be provided as salts with pharmaceutically compatible counterions. Pharmaceutically compatible salts may be formed with many acids, including but not limited to hydrochloric,

sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents that are the corresponding free base forms.

#### 4.3.3. Effective Dosage.

5       Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve its intended purpose. More specifically, a therapeutically effective amount means  
10       an amount effective to prevent development of or to alleviate the existing symptoms of the subject being treated. Determination of the effective amounts is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.

15       For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. For example, a dose can be formulated in animal models to achieve a circulating concentration range that  
20       includes the  $IC_{50}$  as determined in cell culture (i.e., the concentration of the test compound which achieves a half-maximal inhibition of the PTK activity). Such information can be used to more accurately determine useful doses in humans.

25       A therapeutically effective dose refers to that amount of the compound that results in amelioration of symptoms or a prolongation of survival in a patient. Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical  
30       procedures in cell cultures or experimental animals, e.g., for determining the  $LD_{50}$  (the dose lethal to 50% of the population) and the  $ED_{50}$  (the dose therapeutically effective in 50% of the population).  
35       The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as

the ratio between LD<sub>50</sub> and ED<sub>50</sub>. Compounds which exhibit high therapeutic indices are preferred. The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED<sub>50</sub> with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g. Fingl et al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 pl).

Dosage amount and interval may be adjusted individually to provide plasma levels of the active moiety which are sufficient to maintain the kinase modulating effects, or minimal effective concentration (MEC). The MEC will vary for each compound but can be estimated from *in vitro* data; e.g. the concentration necessary to achieve 50-90% inhibition of the kinase using the assays described herein. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. However, HPLC assays or bioassays can be used to determine plasma concentrations.

Dosage intervals can also be determined using MEC value. Compounds should be administered using a regimen which maintains plasma levels above the MEC for 10-90% of the time, preferably between 30-90% and most preferably between 50-90%. In cases of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration.

The amount of composition administered will, of course, be dependent on the subject being treated, on the subject's weight, the severity of the affliction,

the manner of administration and the judgment of the prescribing physician.

#### 4.3.4. Packaging

The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. Compositions comprising a compound of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labelled for treatment of an indicated condition. Suitable conditions indicated on the label may include treatment of a tumor, inhibition of angiogenesis, treatment of fibrosis, diabetes, and the like.

#### 5. EXAMPLE: Compound Synthesis

The compounds of the present invention may be synthesized according to known techniques. The following represent preferred methods for synthesizing the compounds of the claimed invention:

##### 5.1. Synthesis Of 6,8-Dichloro-2-(4-fluorophenyl)-3-nitro-1,2-benzopyran

The preferred method for synthesizing 6,8-Dichloro-2-(4-fluorophenyl)-3-nitro-1,2-benzopyran is as follows: 4-Fluoro- $\beta$ -nitrostyrene was prepared by condensation of 4-fluorobenzaldehyde and nitromethane in the presence of base (Henry reaction). 3,5-Dichloro-5-hydroxybenzaldehyde (0.382 g) and 4-fluoro- $\beta$ -nitrostyrene (367 mg, 1.1 eq) were stirred in 3 ml of pyridine for 48 hours at room temperature. The reaction was partitioned in a mixture of ethyl acetate and 2 N hydrochloric acid. The ethyl acetate layer was washed once with 2 N hydrochloric acid, once with saturated sodium bicarbonate, once with brine, dried over anhydrous magnesium sulfate, filtered and

evaporated to dryness. Chromatography of the residue on silica gel in methylene chloride and methanol gave 0.2 g of 6,8-dichloro-2-(4-fluorophenyl)-3-nitro-1,2-benzopyran, a yellow solid.

**5.2. Synthesis Of 2-(4-Fluorophenyl)-8-methoxy-3-nitro-1,2-benzopyran**

5 The preferred method for synthesizing 2-(4-Fluorophenyl)-8-methoxy-3-nitro-1,2-benzopyran (Compound A) is as follows: A mixture of 2-hydroxy-3-methoxybenzaldehyde (304 mg) and 4-fluoro- $\beta$ -nitrostyrene (367 mg, 1.1 eq) was stirred in 3 ml of  
10 pyridine for 48 hours at room temperature as disclosed in section 5.1. The reaction was partitioned in a mixture of ethyl acetate and 2 N hydrochloric acid. The ethyl acetate layer was washed once with 2 N hydrochloric acid, once with saturated sodium  
15 bicarbonate, once with brine, dried over anhydrous magnesium sulfate, filtered and evaporated to dryness. Chromatography of the residue on silica gel in methylene chloride and methanol gave 0.2 g of 2-(4-fluorophenyl)-8-methoxy-3-nitro-1,2-benzopyran, a  
20 yellow solid.

**5.3. Synthesis Of 6-Chloro-2-(2,4-dichlorophenyl)-3-nitro-1,2-benzopyran**

The preferred method for synthesizing 4-(3-chlorophenyl)-3-cyano-2-(pyrido-2-sulfonyl)thiophene  
25 is as follows: Reaction of 2-hydroxy-5-chlorobenzaldehyde (0.313 g) and 2,4-dichloro- $\beta$ -nitrostyrene (0.480 g) in pyridine as described in section 5.1 gave 6-chloro-2-(2,4-dichlorophenyl)-3-nitro-1,2-benzopyran.

**30 5.4. Synthesis Of 6-Chloro-2-[4-(methylmercapto)phenyl]-3-nitro-1,2-benzopyran**

The preferred method for synthesizing 6-Chloro-2-[4-(methylmercapto)phenyl]-3-nitro-1,2-benzopyran is as follows: Reaction of 2-hydroxy-5-  
35 chlorobenzaldehyde and 4-methylmercapto- $\beta$ -nitrostyrene

as described in section 5.1 gave 6-chloro-2-[4-(methylmercapto)phenyl]-3-nitro-1,2-benzopyran.

**5.5. Synthesis Of 6-Chloro-2-[4-(methylsulfonyl)phenyl]-3-nitro-1,2-benzopyran**

The preferred method for synthesizing 6-Chloro-2-[4-(methylsulfonyl)phenyl]-3-nitro-1,2-benzopyran is as follows: Reaction of 2-hydroxy-5-chlorobenzaldehyde and 4-methoxysulfonyl- $\beta$ -nitrostyrene as described in section 5.1 gave 6-chloro-2-[4-(methylsulfonyl)phenyl]-3-nitro-1,2-benzopyran.

**5.6. Synthesis Of 6-Chloro-3-nitro-2-[4-(phenoxy)phenyl]-1,2-benzopyran**

The preferred method for synthesizing 6-Chloro-3-nitro-2-[4-(phenoxy)phenyl]-1,2-benzopyran is as follows: Reaction of 2-hydroxy-5-chlorobenzaldehyde and 4-phenoxy- $\beta$ -nitrostyrene as described in section 5.1 gave 6-chloro-3-nitro-2-[4-(phenoxy)phenyl]-1,2-benzopyran.

**5.7. Synthesis Of 2-(4-isopropylphenyl)-3-nitro-1,2-benzopyran**

The preferred method for synthesizing 2-(4-isopropylphenyl)-3-nitro-1,2-benzopyran is as follows: Reaction of 2-hydroxybenzaldehyde and 4-isopropyl- $\beta$ -nitrostyrene as described in section 5.1 gave 2-(4-isopropylphenyl)-3-nitro-1,2-benzopyran.

**5.8. Synthesis Of 2-(4-chlorophenyl)naphtho[1,2-e]1,2-pyran**

The preferred method for synthesizing 2-(4-chlorophenyl)naphtho[1,2-e]1,2-pyran: Reaction of 2-hydroxy-1-naphthaldehyde and 4-chloro- $\beta$ -nitrostyrene as described in section 5.1 gave naphtho[1,2-e]2-(4-chlorophenyl)1,2-pyran.



**5.9. Synthesis Of 3-Nitro-2-(thien-2-yl)-1,2-benzopyran**

The preferred method for synthesizing 3-Nitro-2-(thien-2-yl)-1,2-benzopyran is as follows:

Reaction of 2-hydroxybenzaldehyde and 1-nitro-2-(thien-2-yl)ethene as described in section 5.1 gave 3-nitro-2-(thien-2-yl)-1,2-benzopyran.

**5.10. Synthesis Of 2-(2-Methoxyphenyl)-3-nitro-1,2-benzopyran**

The preferred method for synthesizing 2-(2-Methoxyphenyl)-3-nitro-1,2-benzopyran is as follows:

Reaction of 2-hydroxybenzaldehyde and 2-methoxy- $\beta$ -nitrostyrene as described section 5.1 gave 2-(2-methoxyphenyl)-3-nitro-1,2-benzopyran.

**5.11. Synthesis Of 5-Bromo-2-(2-methoxyphenyl)-3-nitro-1,2-benzopyran**

The preferred method for synthesizing 5-Bromo-2-(2-methoxyphenyl)-3-nitro-1,2-benzopyran is as follows: Reaction of 4-bromo-2-hydroxybenzaldehyde and 2-methoxy- $\beta$ -nitrostyrene as described in section 5.1 gave 6-bromo-2-(2-methoxyphenyl)-3-nitro-1,2-benzopyran.

**5.12. Synthesis Of 2-(Benzofuran-2-yl)-3-nitro-1,2-benzopyran**

The preferred method for synthesizing 2-(Benzofuran-2-yl)-3-nitro-1,2-benzopyran is as follows: Reaction of 2-hydroxybenzaldehyde and 1-(benzofuran-2-yl)-2-nitroethene as described in section 5.1 gave 2-(benzofuran-2-yl)-3-nitro-1,2-benzopyran.

**5.13. Synthesis Of 6-Chloro-2-(2-cyanophenyl)-3-nitro-1,2-benzopyran**

The preferred method for synthesizing 6-Chloro-2-(2-cyanophenyl)-3-nitro-1,2-benzopyran is as follows: Reaction of 2-hydroxy-5-chlorobenzaldehyde and 4-cyano- $\beta$ -nitrostyrene as in described 5.1 gave 6-chloro-2-(2-cyanophenyl)-3-nitro-1,2-benzopyran.

**5.14. Synthesis Of 8-Methoxy-3-nitro-2-(2-nitrothien-4-yl)-1,2-benzopyran**

The preferred method for synthesizing 8-Methoxy-3-nitro-2-(2-nitrothien-4-yl)-1,2-benzopyran is as follows: Reaction of 2-hydroxy-3-methoxybenzaldehyde and 1-nitro-2-(2-nitrothien-4-yl)ethene as described in section 5.1 gave 8-methoxy-3-nitro-2-(2-nitrothien-4-yl)-1,2-benzopyran.

**5.15. Synthesis Of 2-(4-Hydroxy-3-methoxyphenyl)-8-methoxy-3-nitro-1,2-benzopyran**

The preferred method for synthesizing 2-(4-Hydroxy-3-methoxyphenyl)-8-methoxy-3-nitro-1,2-benzopyran is as follows: Reaction of 2-hydroxy-3-methoxybenzaldehyde and 4-hydroxy-3-methoxy- $\beta$ -nitrostyrene as described in section 5.1 gave 2-(4-hydroxy-3-methoxyphenyl)-8-methoxy-3-nitro-1,2-benzopyran.

**5.16. Synthesis Of 8-Methoxy-3-nitro-2-(1-phenylpyrazol-3-yl)-1,2-benzopyran**

The preferred method for synthesizing 8-Methoxy-3-nitro-2-(1-phenylpyrazol-3-yl)-1,2-benzopyran is as follows: Reaction of 2-hydroxy-3-methoxybenzaldehyde and 1-nitro-2-(1-phenylpyrazole-3-yl)ethene as described in section 5.1 gave 8-methoxy-3-nitro-2-(1-phenylpyrazol-3-yl)-1,2-benzopyran.

**5.17. Synthesis Of 8-Methoxy-3-nitro-2-(1-methylpyrazol-3-yl)-1,2-benzopyran**

The preferred method for synthesizing 8-Methoxy-3-nitro-2-(1-methylpyrazol-3-yl)-1,2-benzopyran is as follows: Reaction of 2-hydroxy-3-methoxybenzaldehyde and 1-nitro-2-(1-methylpyrazole-3-yl)ethene as described in section 5.1 gave 8-methoxy-3-nitro-2-(1-methylpyrazol-3-yl)-1,2-benzopyran.

5.18.       **Synthesis Of 2-(5-Bromo-2-methoxyphenyl)-8-methoxy-3-nitro-1,2-benzopyran**

The preferred method for synthesizing 2-(5-Bromo-2-methoxyphenyl)-8-methoxy-3-nitro-1,2-benzopyran is as follows: Reaction of 2-hydroxy-3-methoxybenzaldehyde and 5-bromo-2-methoxy- $\beta$ -nitrostyrene as described in section 5.1 gave 2-(5-bromo-2-methoxyphenyl)-8-methoxy-3-nitro-1,2-benzopyran.

5.19.       **Synthesis Of 2-(4-Cyanophenyl)-8-methoxy-3-nitro-1,2-benzopyran**

The preferred method for synthesizing 2-(4-Cyanophenyl)-8-methoxy-3-nitro-1,2-benzopyran is as follows: Reaction of 2-hydroxy-3-methoxybenzaldehyde and 4-cyano- $\beta$ -nitrostyrene as in described in section 5.1 gave 2-(4-cyanophenyl)-8-methoxy-3-nitro-1,2-benzopyran.

5.20.       **Synthesis Of 8-Methoxy-3-nitro-2-(thien-3-yl)-1,2-benzopyran**

The preferred method for synthesizing 8-Methoxy-3-nitro-2-(thien-3-yl)-1,2-benzopyran is as follows: Reaction of 2-hydroxy-3-methoxybenzaldehyde and 1-nitro-2-(thien-3-yl)ethene as described in section 5.1 gave 8-methoxy-3-nitro-2-(thien-3-yl)-1,2-benzopyran.

5.21.       **Synthesis Of 8-Methoxy-3-nitro-2-[3-(trifluoromethyl)phenyl]-1,2-benzopyran**

The preferred method for synthesizing 8-Methoxy-3-nitro-2-[3-(trifluoromethyl)phenyl]-1,2-benzopyran is as follows: Reaction of 2-hydroxy-3-methoxybenzaldehyde and 3-trifluoromethyl- $\beta$ -nitrostyrene as described in section 5.1 gave 8-methoxy-3-nitro-2-[3-(trifluoromethyl)phenyl]-1,2-benzopyran.

**5.22. Synthesis Of 8-Methoxy-3-nitro-2-(thien-2-yl)-1,2-benzopyran**

The preferred method for synthesizing 8-Methoxy-3-nitro-2-(thien-2-yl)-1,2-benzopyran is as follows: Reaction of 2-hydroxy-3-methoxybenzaldehyde and 1-nitro-2-(thien-2-yl)ethene as described in  
5 section 5.1 gave 8-methoxy-3-nitro-2-(thien-2-yl)-1,2-benzopyran.

**5.23. Synthesis Of 6,8-Dichloro-3-nitro-2-[2-hydroxy-3-methoxyphenyl]-1,2-benzopyran**

The preferred method for synthesizing 6,8-Dichloro-3-nitro-2-[2-hydroxy-3-methoxyphenyl]-1,2-benzopyran is as follows: Reaction of 3,5-dichloro-2-hydroxybenzaldehyde and 2-hydroxy-3-methoxy- $\beta$ -nitrostyrene as described in section 5.1 gave 6,8-dichloro-3-nitro-2-[2-hydroxy-3-methoxyphenyl]-1,2-  
15 benzopyran.

**5.24. Synthesis Of 6,8-Dichloro-3-nitro-2-(4-chloro-1-methylpyrazol-3-yl)-1,2-benzopyran**

The preferred method for synthesizing 6,8-Dichloro-3-nitro-2-(4-chloro-1-methylpyrazol-3-yl)-1,2-benzopyran is as follows: Reaction of 3,5-dichloro-2-hydroxybenzaldehyde and 1-(4-chloro-1-methylpyrazol-3-yl)-2-nitroethene as described in  
20 section 5.1 gave 6,8-dichloro-3-nitro-2-(4-chloro-1-methylpyrazol-3-yl)-1,2-benzopyran.

**5.25. Synthesis Of 6,8-Dichloro-3-nitro-2-(3-bromothien-5-yl)-1,2-benzopyran**

The preferred method for synthesizing 6,8-Dichloro-3-nitro-2-(3-bromothien-5-yl)-1,2-benzopyran is as follows: Reaction of 3,5-dichloro-2-hydroxybenzaldehyde and 1-(3-bromothien-5-yl)-2-nitroethene as described in section 5.1 gave 6,8-dichloro-3-nitro-2-(3-bromothien-5-yl)-1,2-benzopyran.  
30

35

**5.26. Synthesis Of 6,8-Dichloro-3-nitro-2-[2,5-dimethoxyphenyl]-1,2- benzopyran**

The preferred method for synthesizing 6,8-Dichloro-3-nitro-2-[2,5-dimethoxyphenyl]-1,2-benzopyran is as follows: Reaction of 3,5-dichloro-2-hydroxybenzaldehyde and 2,5-dimethoxy- $\beta$ -nitrostyrene as described in section 5.1 gave 6,8-dichloro-3-nitro-2-[2,5-dimethoxyphenyl]-1,2- benzopyran.

**5.27. Synthesis Of 6,8-Dichloro-3-nitro-2-(4-t-butylphenyl)-1,2- benzopyran**

The preferred method for synthesizing 6,8-Dichloro-3-nitro-2-(4-t-butylphenyl)-1,2- benzopyran is as follows: Reaction of 3,5-dichloro-2-hydroxybenzaldehyde and 4-t-butyl- $\beta$ -nitrostyrene as described in section 5.1 gave 6,8-dichloro-3-nitro-2-(4-t-butylphenyl)-1,2- benzopyran.

**5.28. Synthesis Of 6,8-Dichloro-3-nitro-2-(4-acetamidophenyl)-1,2- benzopyran**

The preferred method for synthesizing 6,8-Dichloro-3-nitro-2-(4-acetamidophenyl)-1,2- benzopyran is as follows: Reaction of 3,5-dichloro-2-hydroxybenzaldehyde and 4-acetamido- $\beta$ -nitrostyrene as in Example 1 gave 6,8-dichloro-3-nitro-2-(4-acetamidophenyl)-1,2- benzopyran.

**5.29. Synthesis Of 6,8-Dichloro-3-nitro-2-(dioxolo[4,5-c]phenyl)-1,2- benzopyran**

The preferred method for synthesizing 6,8-Dichloro-3-nitro-2-(dioxolo[4,5-c]phenyl)-1,2-benzopyran is as follows: Reaction of 3,5-dichloro-2-hydroxybenzaldehyde and 1-(dioxolo[4,5-c]phenyl)-2-nitroethene as described in section 5.1 gave 6,8-dichloro-3-nitro-2-(dioxolo[4,5-c]phenyl)-1,2-benzopyran.

**6. EXAMPLES: RTK Assays**

The following assays and animal models may be used to determine the level of activity and effect of the different compounds of the present invention on

one or more of the RTKs. Similar assays can be designed along the same lines for any tyrosine kinase using techniques well known in the art.

#### 6.1. Enzyme Linked Immunosorbent Assay (ELISA)

Enzyme linked immunosorbent assays (ELISA) may be used to detect and measure the presence of tyrosine kinase activity. The ELISA may be conducted according to known protocols which are described in, for example, Voller, et al., 1980, "Enzyme-Linked Immunosorbent Assay," In: *Manual of Clinical Immunology*, 2d ed., edited by Rose and Friedman, pp 359-371 Am. Soc. Of Microbiology, Washington, D.C.

The disclosed protocol may be adapted for determining activity with respect to a specific RTK. As example, the preferred protocols for conducting the ELISA experiments for specific RTKs is provided below. Adaptation of these protocols for determining a compound's activity for other members of the RTK family, as well as non-receptor tyrosine kinases, are within the scope of those in the art.

##### 6.1.1. FLK-1 ELISA

An ELISA assay was conducted to measure the kinase activity of the FLK-1 receptor and more specifically, the inhibition or activation of protein tyrosine kinase activity on the FLK-1 receptor. Specifically, the following assay was conducted to measure kinase activity of the FLK-1 receptor in FLK-1/NIH3T3 cells.

##### Materials And Methods.

**Materials.** The following reagents and supplies were used:

- a. Corning 96-well ELISA plates (Corning Catalog No. 25805-96);
- b. Cappel goat anti-rabbit IgG (catalog no. 55641);
- c. PBS (Gibco Catalog No. 450-1300EB);

- d. TBSW Buffer (50 Mm Tris (Ph 7.2), 150 Mm NaCl and 0.1% Tween-20);
- e. Ethanolamine stock (10% ethanolamine (Ph 7.0), stored at 4°C);
- f. HNTG buffer (20mM HEPES buffer (Ph 7.5), 150mM NaCl, 0.2% Triton X-100, and 10% glycerol);
- g. EDTA (0.5 M (Ph 7.0) as a 100X stock);
- h. Sodium ortho vanadate (0.5 M as a 100X stock);
- i. Sodium pyro phosphate (0.2M as a 100X stock);
- j. NUNC 96 well V bottom polypropylene plates (Applied Scientific Catalog No. AS-72092);
- k. NIH3T3 C7#3 Cells (FLK-1 expressing cells);
- l. DMEM with 1X high glucose L Glutamine (catalog No. 11965-050);
- m. FBS, Gibco (catalog no. 16000-028);
- n. L-glutamine, Gibco (catalog no. 25030-016);
- o. VEGF, PeproTech, Inc. (catalog no. 100-20) (kept as 1 µg/100 µl stock in Milli-Q dH<sub>2</sub>O and stored at -20°C);
- p. Affinity purified anti-FLK-1 antiserum, Enzymology Lab, Sugen, Inc.;
- q. UB40 monoclonal antibody specific for phosphotyrosine, Enzymology Lab, Sugen, Inc. (see, Fendley, et al., 1990, *Cancer Research* 50:1550-1558);
- r. EIA grade Goat anti-mouse IgG-POD (BioRad catalog no. 172-1011);
- s. 2,2-azino-bis(3-ethylbenz-thiazoline-6-sulfonic acid (ABTS) solution (100mM citric acid (anhydrous), 250 Mm Na<sub>2</sub>HPO<sub>4</sub> (Ph 4.0), 0.5 mg/ml ABTS (Sigma catalog no. A-1888)), solution should be stored in dark at 4°C until ready for use;
- t. H<sub>2</sub>O<sub>2</sub> (30% solution) (Fisher catalog no. H325);

- u. ABTS/H<sub>2</sub>O<sub>2</sub> (15ml ABTS solution, 2  $\mu$ l H<sub>2</sub>O<sub>2</sub>) prepared 5 minutes before use and left at room temperature;
- v. 0.2 M HCl stock in H<sub>2</sub>O;
- w. dimethylsulfoxide (100%) (Sigma Catalog No. D-8418); and
- 5 y. Trypsin-EDTA (Gibco BRL Catalog No. 25200-049).

Protocol. The following protocol was used for conducting the assay:

1. Coat Corning 96-well elisa plates with 1.0 $\mu$ g  
10 per well Cappel Anti-rabbit IgG antibody in 0.1M Na<sub>2</sub>CO<sub>3</sub> pH 9.6. Bring final volume to 150  $\mu$ l per well. Coat plates overnight at 4°C. Plates can be kept up to two weeks when stored at 4°C.
2. Grow cells in Growth media (DMEM,  
15 supplemental with 2.0mM L-Glutamine, 10% FBS) in suitable culture dishes until confluent at 37°C, 5% CO<sub>2</sub>.
3. Harvest cells by tyrpsination and seed in  
Corning 25850 polystyrene 96-well roundbottom cell  
20 plates, 25.000 cells/well in 200 $\mu$ l of growth media.
4. Grow cells at least one day at 37°C, 5% CO<sub>2</sub>.
5. Wash cells with D-PBS 1X.
6. Add 200 $\mu$ l/well of starvation media (DMEM,  
2.0mM l-Glutamine, 0.1% FBS). Incubate overnight at  
25 37°C, 5% CO<sub>2</sub>.
7. Dilute Compounds/Extracts 1:20 in  
polypropylene 96 well plates using starvation media.  
Dilute dimethylsulfoxide 1:20 for use in control  
wells.
8. Remove starvation media from 96 well cell  
30 culture plates and add 162  $\mu$ l of fresh starvation media to each well.
9. Add 18 $\mu$ l of 1:20 diluted Compound/Extract  
dilution (from step 7) to each well plus the 1:20  
35 dimethylsulfoxide dilution to the control wells (+/-



VEGF), for a final dilution of 1:200 after cell stimulation. Final dimethylsulfoxide is 0.5 %. Incubate the plate at 37°C, 5% CO<sub>2</sub> for two hours.

5 10. Remove unbound antibody from ELISA plates by inverting plate to remove liquid. Wash 3 times with TBSW + 0.5% ethanolamine, pH 7.0. Pat the plate on a paper towel to remove excess liquid and bubbles.

11. Block plates with TBSW + 0.5% Ethanolamine, pH 7.0, 150 µl per well. Incubate plate thirty minutes while shaking on a microtiter plate shaker.

10 12. Wash plate 3 times as described in step 10.

13. Add 0.5µg/well affinity purified anti-FLU-1 polyclonal rabbit antiserum. Bring final volume to 150µl/well with TBSW + 0.5% ethanolamine pH 7.0. Incubate plate for thirty minutes while shaking.

15 14. Add 180 µl starvation medium to the cells and stimulate cells with 20µl/well 10.0mM sodium ortho vanadate and 500 ng/ml VEGF (resulting in a final concentration of 1.0mM sodium ortho vanadate and 50ng/ml VEGF per well) for eight minutes at 37°C, 5% CO<sub>2</sub>. Negative control wells receive only starvation medium.

20 15. After eight minutes, media should be removed from the cells and washed one time with 200µl/well PBS.

25 16. Lyse cells in 150µl/well HNTG while shaking at room temperature for five minutes. HNTG formulation includes sodium ortho vanadate, sodium pyro phosphate and EDTA.

30 17. Wash ELISA plate three times as described in step 10.

18. Transfer cell lysates from the cell plate to elisa plate and incubate while shaking for two hours. To transfer cell lysate pipette up and down while scrapping the wells.

35 19. Wash plate three times as described in step 10.

20. Incubate ELISA plate with 0.02 $\mu$ g/well UB40 in TBSW + 0.5% ethanolamine. Bring final volume to 150 $\mu$ l/well. Incubate while shaking for 30 minutes.

21. Wash plate three times as described in step 10.

5 22. Incubate ELISA plate with 1:10,000 diluted EIA grade goat anti-mouse IgG conjugated horseradish peroxidase in TBSW + 0.5% ethanolamine, pH 7.0. Bring final volume to 150 $\mu$ l/well. Incubate while shaking for thirty minutes.

10 23. Wash plate as described in step 10.

24. Add 100  $\mu$ l of ABTS/H<sub>2</sub>O<sub>2</sub> solution to well. Incubate ten minutes while shaking.

15 25. Add 100  $\mu$ l of 0.2 M HCl for 0.1 M HCl final to stop the colordevelopment reaction. Shake 1 minute at room temperature. Remove bubbles with slow stream of air and read the ELISA plate in an ELISA plate reader at 410 nm.

#### 6.1.2. HER-2 ELISA

##### Assay 1: EGF Receptor-HER2 Chimeric Receptor

20 Assay In Whole Cells. HER2 kinase activity in whole EGFR-NIH3T3 cells was measured as described below:

*Materials and Reagents.* The following materials and reagents were used to conduct the assay:

- 25 a. EGF: stock concentration= 16.5 ILM; EGF 201, TOYOBO, Co., Ltd. Japan.
- b. 05-101 (UBI) (a monoclonal antibody recognizing an EGFR extracellular domain).
- c. Anti-phosphotyrosine antibody (anti-Ptyr) (polyclonal)(see, Fendley, et al., supra).
- 30 d. Detection antibody: Goat anti-rabbit IgG horseradish peroxidase conjugate, TAGO, Inc., Burlingame, CA.
- e. TBST buffer:

35 Tris-HCl, pH 7.2 50 mM  
NaCl 150 mM  
Triton X-100 0.1

## f. HNTG 5X stock:

HEPES	0.1 M
NaCl	0.75 M
Glycerol	50%
Triton X-100	1.0%

## g. ABTS stock:

Citric Acid	100 mM
Na <sub>2</sub> HPO <sub>4</sub>	250 mM
HCl, conc.	0.5 pM
ABTS*	0.5mg/ml

\* (2,2'-azinobis(3-ethylbenzthiazolinesulfonic acid)). Keep solution in dark at 4°C until use.

## h. Stock reagents of:

EDTA 100 mM pH 7.0
Na <sub>3</sub> VO <sub>4</sub> 0.5 M
Na <sub>4</sub> (P <sub>2</sub> O <sub>7</sub> ) 0.2 M

15 Procedure. The following protocol was used:

A. Pre-coat ELISA Plate

1. Coat ELISA plates (Corning, 96 well, Cat. #25805-96) with 05-101 antibody at 0.5 g per well in PBS, 100 µl final volume/well, and store overnight at 4°C. Coated plates are good for up to 10 days when stored at 4°C.

2. On day of use, remove coating buffer and replace with 100 µl blocking buffer (5% Carnation Instant Non-Fat Dry Milk in PBS). Incubate the plate, shaking, at room temperature (about 23°C to 25°C) for 30 minutes. Just prior to use, remove blocking buffer and wash plate 4 times with TBST buffer.

B. Seeding Cells

1. An NIH3T3 cell line overexpressing a chimeric receptor containing the EGFR extracellular domain and extracellular HER2 kinase domain can be used for this assay.

2. Choose dishes having 80-90% confluence for the experiment. Trypsinize cells and stop reaction by adding 10% fetal bovine serum. Suspend cells in DMEM

medium (10% CS DMEM medium) and centrifuge once at 1500 rpm, at room temperature for 5 minutes.

3. Resuspend cells in seeding medium (DMEM, 0.5% bovine serum), and count the cells using trypan blue. Viability above 90% is acceptable. Seed cells in DMEM medium (0.5% bovine serum) at a density of 10,000 cells per well, 100  $\mu$ l per well, in a 96 well microtiter plate. Incubate seeded cells in 5% CO<sub>2</sub> at 37°C for about 40 hours.

C. Assay Procedures

1. Check seeded cells for contamination using an inverted microscope. Dilute drug stock (10 mg/ml in DMSO) 1:10 in DMEM medium, then transfer 5  $\mu$ l to a TBST well for a final drug dilution of 1:200 and a final DMSO concentration of 1%. Control wells receive DMSO alone. Incubate in 5% CO<sub>2</sub> at 37°C for two hours.

2. Prepare EGF ligand: dilute stock EGF in DMEM so that upon transfer of 10  $\mu$ l dilute EGF (1:12 dilution), 100 nM final concentration is attained.

3. Prepare fresh HNTG\* sufficient for 100  $\mu$ l per well; and place on ice.

HNTG\* (10 ml):

HNTG stock	2.0 ml
milli-Q H <sub>2</sub> O	7.3 ml
EDTA, 100 mM, pH 7.0	0.5 ml
Na <sub>3</sub> VO <sub>4</sub> , 0.5 M	0.1 ml
Na <sub>4</sub> (P <sub>2</sub> O <sub>7</sub> ), 0.2 M	0.1 ml

4. After 120 minutes incubation with drug, add prepared SGF ligand to cells, 10  $\mu$ l per well, to a final concentration of 100 nM. Control wells receive DMEM alone. Incubate, shaking, at room temperature, for 5 minutes.

5. Remove drug, EGF, and DMEM. Wash cells twice with PBS. Transfer HNTG\* to cells, 100  $\mu$ l per well. Place on ice for 5 minutes. Meanwhile, remove blocking buffer from other ELISA plate and wash with TBST as described above.

6. With a pipette tip securely fitted to a micropipettor, scrape cells from plate and homogenize cell material by repeatedly aspirating and dispensing the HNTG lysis buffer. Transfer lysate to a coated, blocked, and washed ELISA plate. Incubate shaking at room temperature for one hour.

7. Remove lysate and wash 4 times with TBST. Transfer freshly diluted anti-Ptyr antibody to ELISA plate at 100  $\mu$ l per well. Incubate shaking at room temperature for 30 minutes in the presence of the anti-Ptyr antiserum (1:3000 dilution in TBST).

8. Remove the anti-Ptyr antibody and wash 4 times with TBST. Transfer the freshly diluted TAGO anti-rabbit IgG antibody to the ELISA plate at 100  $\mu$ l per well. Incubate shaking at room temperature for 30 minutes (anti-rabbit IgG antibody: 1:3000 dilution in TBST).

9. Remove TAGO detection antibody and wash 4 times with TBST. Transfer freshly prepared ABTS/H<sub>2</sub>O<sub>2</sub> solution to ELISA plate, 100  $\mu$ l per well. Incubate shaking at room temperature for 20 minutes. (ABTS/H<sub>2</sub>O<sub>2</sub> solution: 1.0  $\mu$ l 30% H<sub>2</sub>O<sub>2</sub> in 10 ml ABTS stock).

10. Stop reaction by adding 50  $\mu$ l 5N H<sub>2</sub>SO<sub>4</sub> (optional), and determine O.D. at 410 nm.

11. The maximal phosphotyrosine signal is determined by subtracting the value of the negative controls from the positive controls. The percent inhibition of phosphotyrosine content for extract-containing wells is then calculated, after subtraction of the negative controls.

**Assay 2: HER-2-BT474 ELISA.** A second assay may be conducted to measure whole cell HER2 activity. Such assay may be conducted as follows:

**Materials And Reagents.** The following materials and reagents were used:

- a. BT-474 (ATCC HBT20), a human breast tumor cell line which expresses high levels of HER2 kinase.
- 5 b. Growth media comprising RPMI + 10% FBS + GMS-G (Gibco supplement) + glutamine for use in growing BT-474 in an incubator with 5% CO<sub>2</sub> at 37°C.
- c. A monoclonal anti-HER2 antibody.
- d. D-PBS:
  - 10 KH<sub>2</sub>HPO<sub>4</sub> 0.20 g/l 10 (GIBCO, 310-4190AJ)
  - K<sub>2</sub>HPO<sub>4</sub> 2.16 g/l
  - KCl 0.20 g/l
  - NaCl 8.00 g/l (pH 7.2)
- e. Blocking Buffer: TBST plus 5% Milk (Carnation Instant Non-Fat Dry Milk).
- 15 f. TBST buffer:
  - Tris-HCl 50 mM
  - NaCl 150 mM (pH 7.2, HCl 10 N)
  - Triton X-100 0.1%
- 20 wherein stock solution of TES (10X) is prepared, and Triton X-100 is added to the buffer during dilution.
- g. HNTG buffer (5x):
  - 25 HEPES 0.1 M
  - NaCl 750 mM (pH 7.2 (HCl, 1 N)
  - Glycerol 50%
  - Triton X-100 1.0%
- Stock solution (5x) is prepared and kept in 4°C.
- h. EDTA-HCl: 0.5 M pH 7.0 (10 N HCl) as 500X stock.
- 30 i. Na<sub>3</sub>VO<sub>4</sub>: 0.5 M as 100X stock is kept at -80°C as aliquots.
- j. Na<sub>4</sub>P<sub>2</sub>O<sub>7</sub>: 0.2 M as 100X stock.
- k. Polyclonal antiserum anti-phosphotyrosine.
- 35

1. Goat anti-rabbit IgG, horseradish peroxidase (POD) conjugate (detection antibody), Tago (Cat. No. 4520; Lot No. 1802): Tago, Inc., Burlingame, CA.

m. ABTS solution:

5 Citric acid 100 mM  
Na<sub>2</sub>HPO<sub>4</sub> 250 mM (pH 4.0, 1 N HCl)  
ABTS 0.5 mg/ml

wherein ABTS is 2,2'-azinobis(3-ethylbenzthiazoline sulfonic acid). For this assay, the ABTS solution should be kept in the dark at 4°C. The solution should be discarded when it turns green.

10

- n. Hydrogen peroxide: 30% solution is kept in dark and 4°C.

*Procedure.* All the following steps are at room temperature and aseptically, unless stated otherwise. All ELISA plate washing is by rinsing with distilled water three times and once with TBST.

15

A. Cell Seeding

1. Grow BT474 cells in tissue culture dishes (Corning 25020-100) to 80-90% confluence and collect using Trypsin-EDTA (0.25%, GIBCO).

20

2. Resuspend the cells in fresh medium and transfer to 96-well tissue culture plates (Corning, 25806-96) at about 25,000-50,000 cells/well (100 µl/well). Incubate the cells in 5% CO<sub>2</sub> at 37°C overnight.

25

B. ELISA Plate Coating and Blocking

1. Coat the ELISA plate (Corning 25805-96) with anti HER2 antibody at 0.5 µg/well in 150 µl PBS overnight at 4°C, and seal with parafilm. The antibody coated plates can be used up to 2 weeks, when stored at 4°C.

30

2. On the day of use, remove the coating solution, replace with 200 µl of Blocking Buffer, shake the plate, and then remove the blocking buffer and wash the plate just before adding lysate.

35

C. Assay Procedures

1. TBST the drugs in serum-free condition.  
Before adding drugs, the old media is replaced with serum-free RPMI (90  $\mu$ l/well)

2. Dilute drug stock (in 100% DMSO) 1:10 with RPMI, and transfer 10  $\mu$ l/well of this solution to the cells to achieve a final drug DMSO concentration at 1%. Incubate the cells in 5% CO<sub>2</sub> at 37°C.

3. Prepare fresh cell lysis buffer (HNTG\*)

5xHNTG	2 ml
EDTA	0.2 ml
Na <sub>3</sub> VO <sub>4</sub>	0.1 ml
Na <sub>4</sub> P <sub>2</sub> O <sub>7</sub>	0.1 ml
H <sub>2</sub> O	7.3 ml

4. After drug preincubation for two hours remove all the solution from the plate, transfer HNTG\* (100  $\mu$ l/well) to the cells, and shake for 10 minutes.

5. Use a 12-channel pipette to scrape the cells from the plate, and homogenize the lysate by repeat aspiration and dispensing. Transfer all the lysate to the ELISA plate and shake for 1 hour.

6. Remove the lysate, wash the plate, add anti-pTyr (1:3,000 with TBST) 100  $\mu$ l/well, and shake for 30 minutes.

7. Remove anti-pTyr, wash the plate, add goat anti-rabbit IgG conjugated antibody (1:5,000 with TBST) 100  $\mu$ l/well, and shake for 30 minutes.

8. Remove anti-rabbit IgG antibody, wash the plate, and add fresh ABTS/H<sub>2</sub>O<sub>2</sub> (1.2  $\mu$ l H<sub>2</sub>O<sub>2</sub> to 10 ml ABTS) 100  $\mu$ l/well to the plate to start color development, which usually takes 20 minutes.

9. Measure OD 410 nm, Dynatec MR5000.

#### 6.1.3. PDGF-R ELISA

All cell culture media, glutamine, and fetal bovine serum were purchased from Gibco Life Technologies (Grand Island, NY) unless otherwise specified. All cells were grown in a humid atmosphere of 90-95% air and 5-10% CO<sub>2</sub> at 37°C. All cell lines



were routinely subcultured twice a week and were negative for mycoplasma as determined by the Mycotect method (Gibco).

For ELISA assays, cells (U1242, obtained from Joseph Schlessinger, NYU) were grown to 80-90% confluency in growth medium (MEM with 10% FBS, NEAA, 1 mM NaPyr and 2 mM GLN) and seeded in 96-well tissue culture plates in 0.5% serum at 25,000 to 30,000 cells per well. After overnight incubation in 0.5% serum-containing medium, cells were changed to serum-free medium and treated with test compound for 2 hr in a 5% CO<sub>2</sub>, 37°C incubator. Cells were then stimulated with ligand for 5-10 minute followed by lysis with HNTG (20 mM Hepes, 150 mM NaCl, 10% glycerol, 5 mM EDTA, 5 mM Na<sub>3</sub>VO<sub>4</sub>, 0.2% Triton X-100, and 2 mM NaPyr). Cell lysates (0.5 mg/well in PBS) were transferred to ELISA plates previously coated with receptor-specific antibody and which had been blocked with 5% milk in TBST (50 mM Tris-HCl pH 7.2, 150 mM NaCl and 0.1% Triton X-100) at room temperature for 30 min. Lysates were incubated with shaking for 1 hour at room temperature. The plates were washed with TBST four times and then incubated with polyclonal anti-phosphotyrosine antibody at room temperature for 30 minutes. Excess anti-phosphotyrosine antibody was removed by rinsing the plate with TBST four times. Goat anti-rabbit IgG antibody was added to the ELISA plate for 30 min at room temperature followed by rinsing with TBST four more times. ABTS (100 mM citric acid, 250 mM Na<sub>2</sub>HPO<sub>4</sub> and 0.5 mg/mL 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid)) plus H<sub>2</sub>O<sub>2</sub> (1.2 mL 30% H<sub>2</sub>O<sub>2</sub> to 10 ml ABTS) was added to the ELISA plates to start color development. Absorbance at 410

35

nm with a reference wavelength of 630 nm was recorded about 15 to 30 min after ABTS addition.

#### 6.1.4. IGF-I ELISA

The following protocol may be used to measure phosphotyrosine level on IGF-I receptor, which indicates IGF-I receptor tyrosine kinase activity.

**Materials And Reagents.** The following materials and reagents were used:

- a. The cell line used in this assay is 3T3/IGF-1R, a cell line which overexpresses IGF-1 receptor.
- b. NIH3T3/IGF-1R is grown in an incubator with 5% CO<sub>2</sub> at 37°C. The growth media is DMEM + 10% FBS (heat inactivated) + 2mM L-glutamine.
- c. Anti-IGF-1R antibody named 17-69 is used. Antibodies are purified by the Enzymology Lab, SUGEN, Inc.
- d. D-PBS:

KH <sub>2</sub> PO <sub>4</sub>	0.20 g/l
K <sub>2</sub> HPO <sub>4</sub>	2.16 g/l
KCl	0.20 g/l
NaCl	8.00 g/l (pH 7.2)
- e. Blocking Buffer: TBST plus 5% Milk (Carnation Instant Non-Fat Dry Milk).
- f. TBST buffer:

Tris-HCl	50 mM
NaCl	150mM (pH 7.2/HCl 10N)
Triton X-100	0.1%

Stock solution of TBS (10X) is prepared, and Triton X-100 is added to the buffer during dilution.
- g. HNTG buffer:

HEPES	20 mM
NaCl	150 mM (pH 7.2/HCl 1N)
Glycerol	10%
Triton X-100	0.2%

Stock solution (5X) is prepared and kept at 4°C.
- h. EDTA/HCl: 0.5 M pH 7.0 (NaOH) as 100X stock.

- i.  $\text{Na}_3\text{VO}_4$ : 0.5 M as 100X stock and aliquots are kept in  $-80^\circ\text{C}$ .
- j.  $\text{Na}_4\text{P}_2\text{O}_7$ : 0.2 M as 100X stock.
- k. Insulin-like growth factor-1 from Promega (Cat# G5111).
- 5 l. Polyclonal antiserum anti-phosphotyrosine: rabbit sera generated by Enzymology Lab., SUGEN Inc.
- m. Goat anti-rabbit IgG, POD conjugate (detection antibody), Tago (Cat. No. 4520, Lot No. 1802): Tago, Inc., Burlingame, CA.
- 10 n. ABTS (2,2'-azino-bis(3-ethylbenzthiazolinesulfonic acid)) solution:

Citric acid	100 mM
$\text{Na}_2\text{HPO}_4$	250 mM (pH 4.0/1 N HCl)
ABTS	0.5 mg/ml
- 15 o. ABTS solution should be kept in dark and  $4^\circ\text{C}$ . The solution should be discarded when it turns green.
- o. Hydrogen Peroxide: 30% solution is kept in the dark and at  $4^\circ\text{C}$ .

**Procedure.** All the following steps are conducted at room temperature unless it is specifically indicated. All ELISA plate washings are performed by rinsing the plate with tap water three times, followed by one TBST rinse. Pat plate dry with paper towels.

**A. Cell Seeding:**

- 25 1. The cells, grown in tissue culture dish (Corning 25020-100) to 80-90% confluence, are harvested with Trypsin-EDTA (0.25%, 0.5 ml/D-100, GIBCO).
- 30 2. Resuspend the cells in fresh DMEM + 10% FBS + 2mM L-Glutamine, and transfer to 96 - well tissue culture plate (Corning, 25806-96) at 20,000 cells/well (100  $\mu\text{l}$ /well). Incubate for 1 day then replace medium to serum-free medium (90/ $\mu\text{l}$ ) and incubate in 5%  $\text{CO}_2$  and  $37^\circ\text{C}$  overnight.

**35 B. ELISA Plate Coating and Blocking:**

1. Coat the ELISA plate (Corning 25805-96) with Anti-IGF-1R Antibody at 0.5  $\mu$ g/well in 100  $\mu$ l PBS at least 2 hours.

2. Remove the coating solution, and replace with 100  $\mu$ l Blocking Buffer, and shake for 30 minutes. Remove the blocking buffer and wash the plate just before adding lysate.

C. Assay Procedures:

1. The drugs are tested in serum-free condition.

2. Dilute drug stock (in 100% DMSO) 1:10 with DMEM in 96-well poly-propylene plate, and transfer 10  $\mu$ l/well of this solution to the cells to achieve final drug dilution 1:100, and final DMSO concentration of 1.0%. Incubate the cells in 5% CO<sub>2</sub> at 37°C for 2 hours.

3. Prepare fresh cell lysis buffer (HNTG\*)

HNTG	2 ml
EDTA	0.1 ml
Na <sub>3</sub> VO <sub>4</sub>	0.1 ml
Na <sub>4</sub> (P <sub>2</sub> O <sub>7</sub> )	0.1 ml
H <sub>2</sub> O	7.3 ml

4. After drug incubation for two hours, transfer 10  $\mu$ l/well of 200nM IGF-1 Ligand in PBS to the cells (Final Conc. = 20 nM), and incubate at 5% CO<sub>2</sub> at 37°C for 10 minutes.

5. Remove media and add 100 $\mu$ l/well HNTG\* and shake for 10 minutes. Look at cells under microscope to see if they are adequately lysed.

6. Use a 12-channel pipette to scrape the cells from the plate, and homogenize the lysate by repeat aspiration and dispense. Transfer all the lysate to the antibody coated ELISA plate, and shake for 1 hour.

7. Remove the lysate, wash the plate, transfer anti-pTyr (1:3,000 with TBST) 100  $\mu$ l/well, and shake for 30 minutes.

8. Remove anti-pTyr, wash the plate, transfer Tago (1:3,000 with TBST) 100  $\mu$ l/well, and shake for 30 minutes.

9. Remove detection antibody, wash the plate, and transfer fresh ABTS/H<sub>2</sub>O<sub>2</sub> (1.2  $\mu$ l H<sub>2</sub>O<sub>2</sub> to 10 ml ABTS) 100  $\mu$ l/well to the plate to start color development.

10. Measure OD in Dynatec MR5000, which is connected to Ingres.

#### 6.1.5. EGF Receptor ELISA

EGF Receptor kinase activity (EGFR-NIH3T3 assay) in whole cells was measured as described below:

**Materials and Reagents.** The following materials and reagents were used

a. EGF Ligand: stock concentration = 16.5  $\mu$ M; EGF 201, TOYOBO, Co., Ltd. Japan.

b. 05-101 (UBI) (a monoclonal antibody recognizing an EGFR extracellular domain).

c. Anti-phosphotyrosine antibody (anti-Ptyr) (polyclonal).

d. Detection antibody: Goat anti-rabbit IgG horse radish peroxidase conjugate, TAGO, Inc., Burlingame, CA.

e. TBST buffer:

Tris-HCl, pH 7	50 mM
NaCl	150 mM
Triton X-100	0.1

f. HNTG 5X stock:

HEPES	0.1 M
NaCl	0.75 M
Glycerol	50
Triton X-100	1.0%

g. ABTS stock:

Citric Acid	100 mM
Na <sub>2</sub> HPO <sub>4</sub>	250 mM
HCl, conc.	4.0 pH

ABTS 0.5 mg/ml

Keep solution in dark at 4°C until used.

## h. Stock reagents of:

EDTA 100 mM pH 7.0  
Na<sub>2</sub>VO<sub>4</sub> 0.5 M  
Na<sub>4</sub>(P<sub>2</sub>O<sub>7</sub>) 0.2 M

Procedure. The following protocol was used:

A. Pre-coat ELISA Plate

- 5 1. Coat ELISA plates (Corning, 96 well, Cat. #25805-96) with 05-101 antibody at 0.5 µg per well in PBS, 150 µl final volume/well, and store overnight at 4°C. Coated plates are good for up to 10 days when stored at 4°C.
- 10 2. On day of use, remove coating buffer and replace with blocking buffer (5% Carnation Instant NonFat Dry Milk in PBS). Incubate the plate, shaking, at room temperature (about 23°C to 25°C) for 30 minutes. Just prior to use, remove blocking buffer and
- 15 wash plate 4 times with TBST buffer.

B. Seeding Cells

1. NIH 3T3/C7 cell line (Honegger, et al., Cell 51:199-209, 1987) can be use for this assay.
2. Choose dishes having 80-90% confluence for
- 20 the experiment. Trypsinize cells and stop reaction by adding 10% CS DMEM medium. Suspend cells in DMEM medium (10% CS DMEM medium) and centrifuge once at 1000 rpm, and once at room temperature for 5 minutes.
3. Resuspend cells in seeding medium (DMEM,
- 25 0.5% bovine serum), and count the cells using trypan blue. Viability above 90% is acceptable. Seed cells in DMEM medium (0.5% bovine serum) at a density of 10,000 cells per well, 100 µl per well, in a 96 well microtiter plate. Incubate seeded cells in 5% CO<sub>2</sub> at
- 30 37°C for about 40 hours.

C. Assay Procedures.

1. Check seeded cells for contamination using an inverted microscope. Dilute drug stock (10 mg/ml in DMSO) 1:10 in DMEM medium, then transfer 5 µl to a
- 35 test well for a final drug dilution of 1:200 and a

final DMSO concentration of 1%. Control wells receive DMSO alone. Incubate in 5% CO<sub>2</sub> at 37°C for one hour.

2. Prepare EGF ligand: dilute stock EGF in DMEM so that upon transfer of 10 µl dilute EGF (1:12 dilution), 25 nM final concentration is attained.

5 3. Prepare fresh 10 ml HNTG\* sufficient for 100 µl per well wherein HNTG\* comprises: HNTG stock (2.0 ml), milli-Q H<sub>2</sub>O (7.3 ml), EDTA, 100 mM, pH 7.0 (0.5 ml), Na<sub>3</sub>VO<sub>4</sub> 0.5 M (0.1 ml) and Na<sub>4</sub> (P<sub>2</sub>O<sub>7</sub>), 0.2 M (0.1 ml).

10 4. Place on ice.

5. After two hours incubation with drug, add prepared EGF ligand to cells, 10 µl per well, to yield a final concentration of 25 nM. Control wells receive DMEM alone. Incubate, shaking, at room temperature, for 5 minutes.

15 6. Remove drug, EGF, and DMEM. Wash cells twice with PBS. Transfer HNTG\* to cells, 100 µl per well. Place on ice for 5 minutes. Meanwhile, remove blocking buffer from other ELISA plate and wash with TBST as described above.

20 7. With a pipette tip securely fitted to a micropipettor, scrape cells from plate and homogenize cell material by repeatedly aspirating and dispensing the HNTG\* lysis buffer. Transfer lysate to a coated, blocked, and washed ELISA plate. Incubate shaking at room temperature for one hour.

25 8. Remove lysate and wash 4 times with TBST. Transfer freshly diluted anti-Ptyr antibody to ELISA plate at 100 µl per well. Incubate shaking at room temperature for 30 minutes in the presence of the anti-Ptyr antiserum (1:3000 dilution in TBST).

30 9. Remove the anti-Ptyr antibody and wash 4 times with TBST. Transfer the freshly diluted TAGO 30 anti-rabbit IgG antibody to the ELISA plate at 100 µl per well. Incubate shaking at room temperature for 30

35

minutes (anti-rabbit IgG antibody: 1:3000 dilution in TBST).

10. Remove detection antibody and wash 4 times with TBST. Transfer freshly prepared ABTS/H<sub>2</sub>O<sub>2</sub> solution to ELISA plate, 100 µl per well. Incubate at room temperature for 20 minutes. ABTS/H<sub>2</sub>O<sub>2</sub> solution: 1.2 µl 30% H<sub>2</sub>O<sub>2</sub> in 10 ml ABTS stock.

11. Stop reaction by adding 50 µl 5N H<sub>2</sub>SO<sub>4</sub> (optional), and determine O.D. at 410 nm.

12. The maximal phosphotyrosine signal is determined by subtracting the value of the negative controls from the positive controls. The percent inhibition of phosphotyrosine content for extract-containing wells is then calculated, after subtraction of the negative controls.

#### 6.1.6. Cellular Insulin Receptor ELISA

The following protocol was used to determine whether the compounds of the present invention possessed insulin receptor tyrosine kinase activity.

**Materials And Reagents.** The following materials and reagents were used to measure phosphotyrosine levels on the insulin receptor (indicating insulin receptor tyrosine kinase activity):

1. The preferred cell line was an NIH3T3 cell line (ATCC 1658) which overexpresses Insulin Receptor (H25 cells);

2. H25 cells are grown in an incubator with 5% CO<sub>2</sub> at 37°C. The growth media is DMEM + 10% FBS (heat inactivated) + 2mm L-Glutamine;

3. For ELISA plate coating, the monoclonal anti-IR antibody named BBE is used. Said antibodies was purified by the Enzymology Lab, SUGEN, Inc.;

4. D-PBS, comprising:

KH <sub>2</sub> PO <sub>4</sub>	0.20 g/l (GIBCO, 310-4190AJ)
K <sub>2</sub> HPO <sub>4</sub>	2.16 g/l
KCl	0.20 g/l
NaCl	8.00 g/l (pH 7.2);



5. Blocking Buffer: TBST plus 5% Milk  
(Carnation Instant Non-Fat Dry Milk);

6. TBST buffer, comprising:

Tris-HCl	50mM
NaCl	150mM pH 7.2 (HCl, 1 N)
Triton X-100	0.1%

5 Note: Stock solution of TBS (10X) is prepared, and  
Triton X-100 is added to the buffer during dilution;

7. HNTG buffer, comprising:

HEPES	20mM
NaCl	150mM pH 7.2 (HCl, 1 N)
Glycerol	10%
Triton X-100	0.2%

Note: Stock solution (5X) is prepared and kept at  
4°C;

15 8. EDTA.HCl: 0.5 M pH 7.0 (NaOH) as 100X stock;

9.  $\text{Na}_3\text{VO}_4$ : 0.5 M as 100X stock and aliquots are  
kept in -80°C;

10.  $\text{Na}_4\text{P}_2\text{O}_7$ : 0.2 M as 100X stock;

11. Insulin from GIBCO BRL (Cat# 18125039);

20 12. Polyclonal antiserum Anti-phosphotyrosine:  
rabbit sera generated by Enzymology Lab., SUGEN Inc.;

13. Detection antibody, preferably goat anti-  
rabbit IgG, POD conjugate, Tago (Cat. No. 4520: Lot  
No. 1802): Tago, Inc., Burlingame, CA;

25 14. ABTS solution, comprising:

Citric acid	100 mM
$\text{Na}_2\text{HPO}_4$	250 mM pH 4.0 (1 N HCl)
ABTS	0.5 mg/ml

wherein ABTS is 2,2'-azinobis (3-ethylbenathiazoline  
sulfonic acid) and stored in the dark at 4°C and  
30 discarded when it turns green;

15. Hydrogen Peroxide: 30% solution is kept in  
the dark and at 40°C.

35 **Protocol.** All the following steps are conducted  
at room temperature unless it is specifically  
indicated. All ELISA plate washings are performed by

rinsing the plate with tap water three times, followed by one TBST rinse. All plates were tapped dry with paper towels prior to use.

A. Cell Seeding:

1. The cells were grown in tissue culture dish (10 cm, Corning 25020-100) to 80-90% confluence and harvested with Trypsin-EDTA (0.25%, 0.5 ml/D-100, GIBCO);

2. Resuspend the cells in fresh DMEM + 10% FBS + 2mM L-Glutamine, and transfer to 96 - well tissue culture plate (Corning, 25806-96) at 20,000 cells/well (100  $\mu$ l/well). The cells are then incubated for 1 day. Following such incubation, 0.01% serum medium (90/ $\mu$ l) replaces the old media and the cells incubate in 5% CO<sub>2</sub> and 37°C overnight.

B. ELISA Plate Coating and Blocking:

1. Coat the ELISA plate (Corning 25805-96) with Anti-IR Antibody at 0.5  $\mu$ g/well in 100  $\mu$ l PBS at least 2 hours.

2. Remove the coating solution, and replace with 100  $\mu$ l blocking Buffer, and shake for 30 minutes. Remove the blocking buffer and wash the plate just before adding lysate.

C. Assay Procedures

1. The drugs are tested in serum-free condition.

2. Dilute drug stock (in 100% DMSO) 1:10 with DMEM in 96-well poly-propylene plate, and transfer 10  $\mu$ l/well of this solution to the cells to achieve final drug dilution 1:100, and final DMSO concentration of 1.0%. Incubate the cells in 5% CO<sub>2</sub> at 37°C for 2 hours.

3. Prepare fresh cells lysis buffer (HNTG\*)

HNTG (5x)	2 ml
EDTA	0.1 ml
Na <sub>3</sub> VO <sub>4</sub>	0.1 ml
Na <sub>4</sub> P <sub>2</sub> O <sub>7</sub>	0.1 ml

H<sub>2</sub>O 7.3 ml

HNTG\* 10 ml

4. After drug incubation for two hours, transfer 10 µl/well of 1µM insulin in PBS to the cells (Final conc= 100 nM), and incubate at 5% CO<sub>2</sub> at 37°C for 10 minutes.

5. Remove media and add 100 µl/well HNTG\* and shake for 10 minutes. Look at cells under microscope to see if they are adequately lysed.

6. Using a 12-channel pipette, scrape the cells from the plate, and homogenize the lysate by repeat aspiration and dispense. Transfer all the lysate to the antibody coated ELISA plate, and shake for 1 hour.

7. Remove the lysate, wash the plate, transfer anti-pTyr (1:3,000 with TBST) 100 µl/well, and shake for 30 minutes.

8. Remove anti-pTyr, wash the plate, transfer Tago (1:3,000 with TBST) 100 µl/well, and shake for 30 minutes.

9. Remove detection antibody, wash the plate, and transfer fresh ABTS/H<sub>2</sub>O<sub>2</sub> (1.2 µl H<sub>2</sub>O<sub>2</sub> to 10 ml ABTS) 100 µl/well to the plate to start color development.

10. Measure OD in Dynatec MR5000, which is connected to Ingres. All following steps should follow Ingres instruction.

#### 6.1.7. Experimental Results From ELISA Assays

The experimental results for Compounds 4158 and 4350 using the above-described protocols are set forth at Table 1:

TABLE 1:  
ELISA Assay Results

#	IGF-IR	IR	EGFR	PDGFR	HER-2 BT474	HER-2 3T3	FLK-1 Cell.	FLK-1
A	>100	>100		>50	3.9	11		
B	23.8		<100	>100	8	3.7		

## 6.2. Cell Growth Assays

The following assays may be conducted to measure the effect of the claimed compounds upon cell growth as a result of the compound's interaction with one or more RTKs. Unless otherwise specified, the following assays may be generally applied to measure the activity of a compound against any particular RTK. To the extent that an assay, set forth below, refers to a specific RTK, one skilled in the art would be able to adapt the disclosed protocol for use to measure the activity of a second RTK.

### 6.2.1. Soft Agar Assay

The soft agar assay may be used to measure the effects of substances on cell growth. Unless otherwise stated the soft agar assays were carried out as follows:

**Material And Reagents.** The following materials and reagents were used:

- a. A Water bath set at 39°C and another water bath at 37°C.
- b. 2X assay medium is comprised of 2X Dulbecco's Modified Eagle's Medium (DMEM) (Gibco Cat. # CA400-4ANO3) supplemented by the following:
  - 20% Fetal Bovine Serum (FBS) 2 mM sodium pyruvate 4 mM glutamine amine; and
  - 20 mM HEPES Non-essential Amino Acids (1:50 from 100x stock).
- c. 1X assay medium made of 1X DMEM supplemented with 10% FBS, 1 mM sodium pyruvate, 2 mM glutamine, 10 mM HEPES, non-essential amino acid (1:100 from 100x stock).
- d. 1.6% SeaPlaque Agarose in autoclave bottle.
- e. Sterile 35 mm Corning plates (FMC Bioproducts Cat. #50102).
- f. Sterile 5 ml glass pipets (individually wrapped).

- g. Sterile 15 ml and 50 ml conical centrifuge tubes.
- h. Pipets and sterile tips.
- i. Sterile microcentrifuge tubes.
- j. Cells in T75 flasks: SKOV-3 (ATCC HTB77).
- 5 k. 0.25% Trypsin solution (Gibco #25200-015).

*Procedure.* The following procedure was used to conduct the soft agar assay:

A. Procedure for making the base layer

- 10 1. Have all the media warmed up in the 37°C water bath.
- 2. To make 1X of assay medium + 0.8% agar: make a 1:2 (vol:vol) dilution of melted agar (cooled to 39°C), with 2X assay medium.
- 15 3. Keep all media with agar warm in the 39°C water bath when not in use.
- 4. Dispense 1 ml of 1X assay medium + 0.8% agar into dishes and gently swirl plate to form a uniform base layer. Bubbles should be avoided.
- 20 5. Refrigerate base layers to solidify (about 20 minutes). Base layers can be stored overnight in the refrigerator.

B. Procedure for collecting cells

- 25 1. Take out one flask per cell line from the incubator; aspirate off medium; wash once with PBS and aspirate off; add 3 ml of trypsin solution.
- 2. After all cells dissociate from the flask, add 3 ml of 1X assay media to inhibit trypsin activity. Pipet the cells up and down, then transfer the suspension into a 15ml tube.
- 30 3. Determine the concentration of cells using a Coulter counter, and the viability by trypan blue exclusion.
- 4. Take out the appropriate volume needed to seed 3300 viable cells per plate and dilute it to 1.5 ml with 1X assay medium.
- 35

C. Procedure for making the upper 0.4% agarose layer:

1. Add TBST compounds at twice the desired final assay concentration; + 1.5 ml of cell suspension in 1X assay medium 10% FBS; + 1.5 ml of 1X assay medium + 0.8% agarose\*: Total = 3.0 ml 1X media 10% FBS  
5 + 0.4% agarose with 3300 viable cells/ml, with and without TBST compounds.

\*(Made by 1:2 dilution of 2X media with 1.6% agar 30 for the base layer procedure above.)

10 2. Plate 1 ml of the Assay Mix onto the 1 ml base layer. The duplicates are plated from the 3 ml volume.

3. Incubate the dishes for 2-3 weeks in a 100% humidified, 10% CO<sub>2</sub> incubator.

15 4. Colonies that are 60 microns and larger are scored positive.

6.2.2. **Sulforhodamine B (SRB) Growth Assays**

**Assay 1: MCF-7 RB Growth Assay.** MCF-7 cells are seeded at 2000 cells/well in a 96-well flat bottom  
20 plate in normal growth media, which was 10% FBS/RPMI supplemented with 2 mM Glutamine. The plate of cells is incubated for about 24 hours at 37°C after which it receives an equal volume of compound dilution per well making the total volume per well 200 µl. The compound  
25 is prepared at 2 times the desired highest final concentration and serially diluted in the normal growth media in a 96-well round bottom plate and then transferred to plate of cells. DMSO serves as the vector control up to 0.2% as final concentration. The  
30 cells are then incubated at 37°C in a humidified 5% CO<sub>2</sub> incubator. Four days following dosing of compound, the media is 15 discarded and 200 µl/well of ice-cold 10% TCA (Trichloroacetic Acid) is added to fix cells. After 60 minutes at 4°C, the TCA is discarded and the  
35 plate is rinsed 5 times with water. The plate is then

air-dried and 100  $\mu$ l/well of 0.4% SRB (Sulforhodamine B from Sigma) 20 in 1% Acetic Acid is added to stain cells for 10 minutes at room temperature. The SRB is discarded and the plate is rinsed 5 times with 1% Acetic Acid. After the plate is completely dried, 100  $\mu$ l/well of 10 mM Tris-base is added to solubilize the dye. After 5 to 10 minutes, the plate is read on a Dynatech ELISA Plate Reader at dual wavelengths at 570 nm and 630 nm.

**Assay 2: PDGF-R/SRB Adherent Cells Growth Assay.**

Compounds were tested for inhibition of anchorage-dependent tumor cell growth using the colorimetric assay described by Skehan et al., 1990. *J. Natl. Cancer Inst.* 82:1107-1112. The assay measures protein content of acid-fixed cells using the counterion binding dye sulforhodamine B (SRB, Sigma). The compounds were solubilized in DMSO (Sigma, cell culture grade) and diluted into appropriate growth medium at two-fold the desired final assay concentration. In assays using C6 cells, compounds (100  $\mu$ l) were added to 96-well plates containing attached cellular monolayers (2000 cells/well in 100  $\mu$ l). C6 cells were maintained in Ham's F10 supplemented with 5% fetal bovine serum (FBS) and 2 mM glutamine (GLN). After 4 days (37°C, 5% CO<sub>2</sub>) the monolayers were washed 3 times with PBS and fixed with 200  $\mu$ l ice-cold 10% TCA (Fisher Scientific), and kept at 4°C for 60 min. The TCA was removed and the fixed monolayers were washed 5 times with tap water and allowed to dry completely at room temperature on absorbent paper. The cellular protein was stained for 10 min with 100  $\mu$ l 0.4% SRB dissolved in 1% acetic acid. After 5 washes with tap water, the dye was solubilized in 10 mM Tris base (100  $\mu$ l per well) and absorbance read at 570 nm on a Dynatech plate reader model MR5000. Growth inhibition data are expressed as a percentage of absorbance detected in control wells

which were treated with 0.4% DMSO alone. DMSO controls were not different from cells grown in regular growth medium.  $IC_{50}$  values were determined using a four parameter curve fit function.

For the anchorage-independent tumor cell growth assay, cells (3000 to 5000 per dish) suspended in 0.4% agarose in assay medium (DMEM containing 10% FCS) with and without Compounds were plated into 35 mm dishes coated with a solidified agarose base layer (0.8% agarose). After a 2 to 3 week incubation at 37°C, colonies larger than 50  $\mu$ m were quantified using an Omnicon 3800 Tumor Colony counter.

**Assay 3: MCF-7/HER-2B Growth Assay.** The protocol is basically the same as that above (for the MCF-7 Growth Assay) except that immediately before the 30 compound is added, the normal growth media is removed and 0.5% FBS/RPMI supplemented with 2 mM Glutamine is added onto the cells. The compound is also prepared in this 0.5% serum media. The plate of cells is incubated for four days and developed as usual.

#### 6.2.3. 3T3 Cell Growth Assay

**Assay 1: 3T3/HER2 Cell Growth Assay.**

The NIH3T3 growth assay, using cell lines capable of expressing HER2, was carried out as follows:

**Materials and Reagents.** The following materials and reagents were used:

- a. Dulbecco's Modified Eagle Medium (D-MEM), Gibco 511965-050;
- b. Calf serum, Gibco 16170-029;
- c. Trypsin-EDTA, Gibco 25200-056;
- d. Fetal Bovine Serum Certified, Gibco 16000-028;
- e. Dulbecco' 5 Phosphate-Buffered Saline (D-PBS), Gibco 14190-029;



- f. Sulforhodamine B (SRB), Sigma 5-9012 0.4% SRB in 1% acetic acid;
- g. 10 mM Tris-base, Fisher BP152-5;
- h. 10% TCA, Trichloroacetic acid, Fisher A322-500;
- 5 i. 96-well flat bottom plate (sterile), Corning 08-757-155;
- j. 100 ml reagent reservoir 9 (sterile), Matrix Technologies Corporation, 8086;
- k. Sterile pipet tips, Fisher 21-197-8E;
- 10 l. 50 ml sterile TBST tubes, Fisher 05-539-6; and
- m. NIH3T3C7 cells in 10% CS+2 mM glutamine DMEM  
HER2C7 cells in 2% FBS +2 mM glutamine DMEM

*Procedures.* The following protocol was followed  
15 to conduct the assay:

- 1. HER2C7 (engineered to express HER2) and NIH3T3C7 (as the control) cells are used for this assay. NIH3T3C7 cells are seeded at 2500 cells/well, 10  $\mu$ l/well in 10% CS+2 mM glutamine DMEM, in a 96 well  
20 plate; HER2C7 cells are seeded at 6000 cells/well, 100  $\mu$ l/well in 2% FBS+2 mM glutamine DMEM, in a 96 well plate. Cells are incubated at 37°C, 5% CO<sub>2</sub> overnight to allow for cell attachment to the plate;
- 2. The TBST compound is added to the cells at  
25 day 2. The compounds are prepared in the appropriate growth medium (10% CS + 2 mM) glutamine DMEM for NIH3T3C7 cells; 2% FBS+2 mM glutamine DMEM for HER2C7 cells) in a 96 well plate, and serially diluted. A total of 100  $\mu$ l/well medium of the diluted compounds  
30 is added into the cells. The total volume of each well is 200  $\mu$ l. Quadruplicates (wells) and 11 concentration points are applied to each compound tested.
- 3. After the cells are treated with the  
35 compound for 4 days, the cells are washed with PBS and

fixed with 200  $\mu$ l/well ice-cold 10% TCA for one hour at 0-5°C condition.

4. Remove TCA and rinse wells 5 times with deionized water. Dry plates upside down with paper towels. Stain cells with 0.4% SRB at 100  $\mu$ l/well for 10 minutes.

5. Pour off SRB and rinse plate 5 times with 1% acetic acid. Dry plate completely.

6. Solubilize the dye with 10 mM Tris-base at 100  $\mu$ l/well for 10 minutes on a shaker.

7. Read the plate at dual wavelengths at 570 nm and 630 nm on Dynatech Elisa plate reader.

**Assay 2: IGF-I Receptor Growth Assay**

**Materials And Methods.** The following materials were used to conduct the IGF-I receptor growth assay:

a. The NIH3T3/IGF-1R (10% FBS/2 mM glutamine/DMEM) and NIH3T3 c7 (10% calf serum/2 mM glutamine/DMEM) cell lines were used wherein the NIH3T3 cells (and cells derived from them) were handled such that they were not allowed to become confluent, thus decreasing the likelihood of spontaneous transformation. If the cells showed any signs of being transformed (morphological changes, piling up, moving into clumps), the cells were discarded and new cells were used.

b. 10% FBS/2 mM glutamine/DMEM.

c. 0.5% FBS/2 mM glutamine/DMEM.

d. 10% calf serum/2 mM glutamine/DMEM

e. IGF-1, 5  $\mu$ M in sterile PBS (Promega/Fisher cat. #G5111).

f. DMSO, tissue culture grade (Sigma cat. #D 2650).

g. 100 mM of relevant compound in DMSO.

h. 96-well plates, flat and round bottom.

i. 8 channel pipettor and sterile tips.

j. Sterile reagent reservoirs.

k. Sterile tubes (1.5 or 15 ml).

Using the above described materials, the following steps were performed under aseptic conditions until fixing the cells for the SRB assay:

Day 0: *Cell Plating* - Trypsinize and count  
NIH3T3/IGF-1R and NIH3T3 c7 cells. Dilute  
5 in growth media to 2000 cells/200  $\mu$ l and  
seed flat bottom 96-well plates with 200  
 $\mu$ l/well, one plate for two compounds for  
each cell line.

Day 1: *Compound Preparation* - Add DMSO to each  
10 compound to make 100 mM stock solutions. If  
a compound does not go into solution with  
vortexing, add extra DMSO to make 50 mM or  
less, as required.

15 Aliquot each compound to 3-4 sterile  
screw cap tubes and store at -20°C. After  
thawing, make sure the compound has gone  
completely back into solution. Throw away  
after 3 freeze/thaws.

20 *NIH3T3/IGF-1R cells* - For each 96-well  
plate, make 15 ml of 10 nM IGF-1/0.5% FBS/2  
mM glutamine/DMEM (30  $\mu$ l of 5  $\mu$ M IGF-1/15  
ml).

25 Aliquot 1.5 ml 10 nM IGF-1/0.5% FBS to  
a sterile tube for each compound to be  
tested (the first time a compound is tested,  
use a 15 ml tube in case it is necessary to  
add extra medium to get it into solution).

30 Add 3  $\mu$ l of 100 mM stock of each  
compound to a tube so 200  $\mu$ M final. Shake  
or vortex until it goes into solution. If  
it is necessary to add additional medium,  
note the final concentration.

35 For the DMSO control, prepare 0.5  
ml/plate of 0.2% DMSO/10 nM IGF-1/0.5% FBS  
(2  $\mu$ l DMSO/ml).

For every two compounds, aliquot 130  $\mu$ l 10 nM IGF-1/0.5% FBS to wells in columns 2-11 of a 96-well round bottom plate.

Add 260  $\mu$ l of each compound to four wells in column 12.

5 Do 2-fold dilutions (130  $\mu$ l) from columns 12 to 3 on each plate (column 2 will be for the untreated control), mixing thoroughly.

10 Remove medium from NIH3T3/IGF-1R cells, one plate at a time.

Transfer 120  $\mu$ l from each well on a compound dilution plate to the corresponding well of cells.

15 Add 120  $\mu$ l 0.2% DMSO/10 nM IGF-1/0.5% FBS to four wells in column 1.

Add 120  $\mu$ l 0.5% FBS (without IGF-1) to other four wells in column 1 for negative control.

20 *NIH3T3 c7 cells* - Carry out the same steps as for NIH3T3/IGF-1R cells except use 10% calf serum instead of 0.5% FBS and do not include IGF-1.

Day 4: Refeed - Repeat steps above, adding exactly the same IGF-1 and compound concentration to each well as before.

25 Day 6: *Analysis of cells* - Look at wells with the highest concentrations for each compound to make sure it has not precipitated. If so, mark wells and do not use for data calculations.

30 Also scan plates to make sure none of the wells are contaminated. If so, mark wells and do not use for data calculations.  
35 *Detection* - Follow the steps for fixing and staining described in the SOP for SRB Assays.

Day X: Data analysis - Find averages and standard deviations for each set of four OD's.

Using wells in column 2 (treated with IGF-1 but not compound) as 100%, calculate percent of control for each concentration of compound.

5

Determine the fold difference between the IGF-1-treated and untreated cells. It should be 2-3-fold.

10

Determine the percent of control for 0.2% DMSO. If it is less than 95%, do not use the highest compound concentration to calculate the  $IC_{50}$  value.

Use a curve fit method to graph percent of control vs. log(molar concentration) and determine the  $IC_{50}$ .

15

**Assay 3: NIH3T3/EGFR Cell Growth Assay.**

The following cellular models illustrate the ability of the exemplary compounds to inhibit receptor tyrosine kinases, generally, and HER2 and/or EGFR particularly.

20

(a) NIH3T3 clone C7 (Honegger et al., supra) engineered to over-express human EGF receptor;

(b) NIH3T3 cells engineered to over-express a chimeric receptor containing the EGFR extracellular domain and the HER2 intracellular kinase domain;

25

(c) the human mammary carcinoma line BT474 (ATCC HTB2) expressing HER2; and

(d) the human glioblastoma line U1242 that expresses PDGFR-beta.

30

Growth assays were carried out using human mammary epithelial SKBR3 (ATCC HTB30) cells, SKOV3 (ATCC HTB77) human ovarian cancer cell line, A431 cells, MCF7 human breast carcinoma cells, MCF7 cells overexpress the HER2 kinase (MCF7-HER2), NIH3T3 cells, and NIH3T3 cells overexpressing the HER2 kinase (3T3-HER2)

35

SKBR3 cells over-express HER2. A431 cells over-express EGFR. These cells were dispensed into 96-well plates with test compounds. After 4 days the monolayers were TCA-fixed then stained with sulphorhodamine B. The absorbance versus log drug concentration was plotted and IC<sub>50</sub> values estimated.

SKOV3 cells also over-express HER2. These cells were plated into soft agar with a test compound and colony growth was quantified 2 weeks later using an Omnicon colony counter.

#### 6.2.4. HUV-EC-C Assay

The following protocol may also be used to measure a compound's activity:

##### DAY 0

1. Wash and trypsinize HUV-EC-C cells (human umbilical vein endothelial cells, (American Type Culture Collection; catalogue no. 1730 CRL). Wash with Dulbecco's phosphate-buffered saline (D-PBS; obtained from Gibco BRL; catalogue no. 14190-029) 2 times at about 1 ml/10 cm<sup>2</sup> of tissue culture flask. Trypsinize with 0.05% trypsin-EDTA in non-enzymatic cell dissociation solution (Sigma Chemical Company; catalogue no. C-1544). The 0.05% trypsin was made by diluting 0.25% trypsin/1 mM EDTA (Gibco; catalogue no. 25200-049) in the cell dissociation solution. Trypsinize with about 1 ml/25-30 cm<sup>2</sup> of tissue culture flask for about 5 minutes at 37°C. After cells have detached from the flask, add an equal volume of D-PBS and transfer to a 50 ml sterile centrifuge tube (Fisher Scientific; catalogue no. 05-539-6).

2. Wash the cells with about 35 ml D-PBS in the 50 ml sterile centrifuge tube by adding the D-PBS, centrifuge for 10 minutes at approximately 200xg, aspirate the supernatant, and resuspend with 35 ml D-PBS. Repeat the wash two more times, resuspend the cells in about 1 ml assay medium/15 cm<sup>2</sup> of tissue culture flask. Assay medium consists of F12K medium

(Gibco BRL; catalogue no. 21127-014) + 0.5% heat-inactivated fetal bovine serum. Count the cells with a Coulter Counter® (Coulter Electronics, Inc.) and add assay medium to the cells to obtain a concentration of  $0.8-1.0 \times 10^5$  cells/ml.

- 5           3. Add cells to 96-well flat-bottom plates at 100  $\mu$ l/well or  $0.8-1.0 \times 10^4$  cells/well; incubate ~24h at 37°C, 5% CO<sub>2</sub>.

DAY 1

- 10           1. Make up two-fold drug titrations in separate 96-well plates, generally 50  $\mu$ M on down to 0  $\mu$ M. Use the same assay medium as mentioned in day 0, step 2 above. Titrations are made by adding 120  $\mu$ l/well of drug at 200  $\mu$ M (4X the final well concentration) to the top well of a particular plate column. Since the stock drug concentration is 10 mM and in 100% DMSO, 15 the 200  $\mu$ M drug concentration is 0.5% DMSO.

- Therefore, diluent made up of 0.5% DMSO in assay medium (F12K + 0.5% fetal bovine serum) is used as diluent for the drug titrations in order to dilute the drug but keep the DMSO concentration constant. Add 20 this diluent to the remaining wells in the column at 60  $\mu$ l/well. Take 60  $\mu$ l from the 120  $\mu$ l of 200  $\mu$ M drug dilution in the top well of the column and mix with the 60  $\mu$ l in the second well of the column. Take 60 25  $\mu$ l from this well and mix with the 60  $\mu$ l in the third well of the column, and so on until two-fold titrations are completed. When the next-to-the-last well is mixed, take 60  $\mu$ l of the 120  $\mu$ l in this well and discard it. Leave the last well with 60  $\mu$ l of DMSO/media diluent as a non-drug-containing control. 30 Make 9 columns of titrated drug, enough for triplicate wells each for 1) VEGF (obtained from Pepro Tech Inc., catalogue no. 100-200, 2) endothelial cell growth factor (ECGF) (also known as acidic fibroblast growth factor, or aFGF) (obtained from Boehringer Mannheim 35 Biochemica, catalogue no. 1439 600), and assay media

control. ECGF comes as a preparation with sodium heparin.

2. Transfer 50  $\mu$ l/well of the drug dilutions to the 96-well assay plates containing the  $0.8-1.0 \times 10^4$  cells/100  $\mu$ l/well of the HUV-EC-C cells from day 0 and incubate ~2 h at 37°C, 5% CO<sub>2</sub>.

5 3. In triplicate, add 50  $\mu$ l/well of 80  $\mu$ g/ml VEGF, 20 ng/ml ECGF, or media control to each drug condition. As with the drugs, the growth factor concentrations are 4X the desired final concentration. Use the assay media from day 0 step 2 to make the  
10 concentrations of growth factors. Incubate approximately 24 hours at 37°C, 5% CO<sub>2</sub>. Each well will have 50  $\mu$ l drug dilution, 50  $\mu$ l growth factor or media, and 100  $\mu$ l cells, = 200  $\mu$ l/well total. Thus  
15 the 4X concentrations of drugs and growth factors become 1X once everything has been added to the wells.

DAY 2

1. Add <sup>3</sup>H-thymidine (Amersham; catalogue no. TRK-686) at 1  $\mu$ Ci/well (10  $\mu$ l/well of 100  $\mu$ Ci/ml  
20 solution made up in RPMI media + 10% heat-inactivated fetal bovine serum) and incubate ~24 h at 37°C, 5% CO<sub>2</sub>.  
Note: <sup>3</sup>H-thymidine is made up in RPMI media because all of the other applications for which we use the <sup>3</sup>H-thymidine involve experiments done in RPMI. The media  
25 difference at this step is probably not significant. RPMI was obtained from Gibco BRL, catalogue no. 11875-051.

DAY 3

1. Freeze plates overnight at 20°C.

DAY 4

30 1. Thaw plates and harvest with a 96-well plate harvester (Tomtec Harvester 96<sup>(R)</sup>) onto filter mats (Wallac; catalogue no. 1205-401); read counts on a Wallac Betaplate<sup>(TM)</sup> liquid scintillation counter.

35



### 6.2.5. PDGF-R Cellular Assay

The PDGF cellular kinase assay was carried out as follows: cells are lysed in 0.2 M Hepes, 0.15 M NaCl, 10% V/V glycerol, 0.04% Triton X-100, 5 mM EDTA, 5 mM sodium vanadate and 2 mM Na<sup>+</sup> pyrophosphate; cell lysates are then added to an ELISA plate coated with an anti-PDGF receptor antibody (Genzyme); ELISA plates are coated at 0.5 µg of antibody/well in 150 µl of PBS for 18 hours at 4°C prior to the addition of the lysate; the lysate is incubated in the coated plates for 1 hour and then washed four times in TBST (35 mM Tris-HCl pH 7.0, 0.15 M NaCl, 0.1% Triton X100); anti-phosphotyrosine antibody (100 µl in PBS) is added and the mixture is incubated for 30 minutes at room temperature; the wells were then washed four times in TBST, a secondary antibody conjugated to POD (TAGO) is added to each well, and the treated well are incubated for 30 minutes at room temperature; the wells are then washed four times in TBST, ABTS/H<sub>2</sub>O<sub>2</sub> solution is added to each well and the wells are incubated for two minutes; absorbance is then measured at 410 nm.

### 6.2.6. Experimental Results Of Cell Growth Assay

Results for compound 4158 from the above-described assays are set forth at Table 2:

TABLE 2  
Cell Growth Assays

Comp. #	3T3 IGF-1R 0.5%FBS	3T3 10%FBS	3T3 HER-2 2%FBS	3T3 10%FBS	MCF7 HER-2 0.5%FBS	MCF7 10%FBS
A	2.5	5.6	1.8	70	0.8	2

### 6.3. Measurement Of Cell Toxicity

Therapeutic compounds should be more potent in inhibiting receptor tyrosine kinase activity than in exerting a cytotoxic effect. A measure of the effectiveness and cell toxicity of a compound can be

obtained by determining the therapeutic index:

IC<sub>50</sub>/LD<sub>50</sub>. IC<sub>50</sub>, the dose required to achieve 50% inhibition, can be measured using standard techniques such as those described herein. LD<sub>50</sub>, the dosage which results in 50% toxicity, can also be measured by standard techniques (Mossman, 1983, *J. Immunol. Methods*, 65:55-63), by measuring the amount of LDH released (Korzeniewski and Callewaert, 1983, *J. Immunol. Methods* 64:313; Decker and Lohmann-Matthes, 1988, *J. Immunol. Methods* 115:61), or by measuring the lethal dose in animal models. Compounds with a large therapeutic index are preferred. The therapeutic index should be greater than 2, preferably at least 10, more preferably at least 50.

#### 6.4. In Vivo Animal Models

##### 6.4.1. Xenograft Animal Models

The ability of human tumors to grow as xenografts in athymic mice (e.g., Balb/c, nu/nu) provides a useful in vivo model for studying the biological response to therapies for human tumors. Since the first successful xenotransplantation of human tumors into athymic mice, (Rygaard and Povlsen, 1969, *Acta Pathol. Microbial. Scand.* 77:758-760), many different human tumor cell lines (e.g., mammary, lung, genitourinary, gastrointestinal, head and neck, glioblastoma, bone, and malignant melanomas) have been transplanted and successfully grown in nude mice. Human mammary tumor cell lines, including MCF-7, ZR75-1, and MDA-MB-231, have been established as subcutaneous xenografts in nude mice (Warri et al., 1991, *Int. J. Cancer* 49:616-623; Ozzello and Sordat, 1980, *Eur. J. Cancer* 16:553-559; Osborne et al., 1985, *Cancer Res.* 45:584-590; Seibert et al., 1983, *Cancer Res.* 43:2223-2239).

##### Assay 1: HER2/Xenograft Animal Model

To study the effect of anti-tumor drug candidates on HER2 expressing tumors, the tumor cells should be

able to grow in the absence of supplemental estrogen. Many mammary cell lines are dependent on estrogen for in vivo growth in nude mice (Osborne et al., *supra*), however, exogenous estrogen suppresses HER2 expression in nude mice (Warri et al., *supra*, Dati et al., 1990, *Oncogene* 5:1001-1006). For example, in the presence  
5 of estrogen, MCF-7, ZR-75-1, and T47D cells grow well in vivo, but express very low levels of HER2 (Warri et al., *supra*, Dati et al., *supra*).

The following type of xenograft protocol can be used:

- 10 1) implant tumor cells (subcutaneously) into the hindflank of five- to six-week-old female Balb/c nu/nu athymic mice;
- 2) administer the anti-tumor compound;
- 15 3) measure tumor growth by measuring tumor volume.

The tumors can also be analyzed for the presence of a receptor, such as HER2, EGF or PDGF, by Western and immunohistochemical analyses. Using techniques  
20 known in the art, one skilled in the art can vary the above procedures, for example through the use of different treatment regimes.

**Assay 2: FLK-1/Xenograft Model.**

The ability of the compounds of the present invention to inhibit ovarian, melanoma, prostate, lung  
25 and mammary tumor cell lines established as SC xenografts was examined. These studies were conducted using doses ranging from 12 to 20 mg/kg/day.

**Materials And Methods.** The tumor cells were implanted subcutaneously into the indicated strains of  
30 mice. Treatment was initiated on day 1 post implantation unless otherwise indicated (e.g. treatment of the SCID mouse related to the A375 melanoma cell line began on Day 9). Eight (8) to ten  
35 (10) mice comprised each test group.

Specifically:

*Animals.* Female athymic mice (BALB/c, nu/nu), BALB/c mice, Wistar rats and Fisher 344 rats were obtained from Simonsen Laboratories (Gilroy, CA). Female A/I mice were obtained from Jackson Laboratory (Bar Harbor, ME). DA rats were obtained from B&K Universal, Inc. (Fremont, CA). Athymic R/Nu rats, DBA/2N mice, and BALB/c mice were obtained from Harlan Sprague Dawley (Indianapolis, IN). Female C57BL/6 mice were obtained from Taconic (Germantown, NY). All animals were maintained under clean-room conditions in Micro-isolator cages with Alpha-dri bedding. They received sterile rodent chow and water *ad libitum*.

All procedures were conducted in accordance with the *NIH Guide for the Care and Use Of Laboratory Animals*.

*Subcutaneous Xenograft Model.* Cell lines were grown in appropriate medium as described (See Section 6). Cells were harvested at or near confluency with 0.05% Trypsin-EDTA and pelleted at 450 x g for 10 min. Pellets were resuspended in sterile PBS or media (without FBS) to a suitable concentration indicated in the Figure legends and the cells were implanted into the hindflank of mice. Tumor growth was measured over 3 to 6 weeks using vernier calipers tumor volumes were calculated as a product of length x width x height unless otherwise indicated. P values were calculated using the Students' t-test. su101 in 50 - 100  $\mu$ L excipient (dimethylsulfoxide, PBTE, PBTE6C:D5W, or PBTE:D5W) was delivered by IP injection at concentrations indicated in the Figure legends.

*Intracerebral Xenograft Model.* For the mouse IC model, rat C6 glioma cells were harvested and suspended in sterile PBS at a concentration of  $2.5 \times 10^7$  cells/ml and placed on ice. Cells were implanted into BALB/c, nu/nu mice in the following manner: the frontoparietal scalps of mice were shaved with animal clippers if necessary before swabbing with 70%

ethanol. Animals were anesthetized with isofluorane and the needle was inserted through the skull into the left hemisphere of the brain. Cells were dispensed from Hamilton Gas-tight Syringes using 30 ga 1/2 inch needles fitted with sleeves that allowed only a 3 mm penetration. A repeater dispenser was used for accurate delivery of 4  $\mu$ L of cell suspension. Animals were monitored daily for well-being and were sacrificed when they had a weight loss of about 40% and/or showed neurological symptoms.

For the rat IC model, rats (Wistar, Sprague Dawley, Fisher 344, or athymic R/Nu; approximately 200 g) were anesthetized by an IP injection of 100 mg/kg Ketaset (ketamine hydrochloride; Aveco, Fort Dodge, Iowa) and 5 mg/kg Rompun (xylazine, 2% solution; Bayer, Germany). After onset of anesthesia, the scalp was shaved and the animal was oriented in a stereotaxic apparatus (Stoelting, Wood Dale, IL). The skin at the incision site was cleaned 3 times with alternating swabs of 70% ethanol and 10% Povidone-Iodine. A median 1.0 - 1.5 cm incision was made in the scalp using a sterile surgical blade. The skin was detached slightly and pulled to the sides to expose the sutures on the skull surface. A dental drill (Stopiting, Wood Dale, IL) was used to make a small (1-2 mm diameter) burrhole in the skull approximately 1 mm anterior and 2 mm lateral to the bregma. The cell suspension was drawn into a 50  $\mu$ L Hamilton syringe fitted with a 23 or 25g a standard bevel needle. The syringe was oriented in the burrhole at the level of the arachnoidea and lowered until the tip of the needle was 3 mm deep into the brain structure, where the cell suspension was slowly injected. After cells were injected, the needle was left in the burrhole for 1-2 minutes to allow for complete delivery of the cells. The skull was cleaned and the skin was closed with 2 to 3 sutures. Animals

were observed for recovery from surgery and anesthesia. Throughout the experiment, animals were observed at least twice each day for development of symptoms associated with progression of intracerebral tumor. Animals displaying advanced symptoms (leaning, loss of balance, dehydration, loss of appetite, loss of coordination, cessation of grooming activities, and/or significant weight loss) were humanely sacrificed and the organs and tissues of interest were resected.

*Intraperitoneal Model.* Cell lines were grown in the appropriate media. Cells were harvested and washed in sterile PBS or medium without FBS, resuspended to a suitable concentration, and injected into the IP cavity of mice of the appropriate strain. Mice were observed daily for the occurrence of ascites formation. Individual animals were sacrificed when they presented with a weight gain of 40%, or when the IP tumor burden began to cause undue stress and pain to the animal.

#### 6.4.2. In Vivo VEGF Pellet Model

In the following example, the Pellet Model was used in connection with testing a compound's activity against the FLK-1 receptor. More specifically, in order to determine the whether a compound is an effective FLK-1 inhibitor to disorders associated with the presence of VEGF, and more specifically, whether a compound may effectively inhibit the formation of blood vessels, a VEGF pellet model for designed. In this model, VEGF is packaged into a time-release pellet and implanted subcutaneously on the abdomen of nude mice to induce a 'reddening' response and subsequent swelling around the pellet. Potential FLK-1 inhibitors may then be implanted in methylcellulose near the VEGF pellet to determine whether such inhibitor may be used to

inhibit the "reddening" response and subsequent swelling.

**Materials And Methods.** The following materials were used:

1) VEGF- human recombinant lyophilized product is commercially may be obtained from Peprotech, Inc.,  
5 Princeton Business Park, G2; P.O. box 275, Rocky Hill, NJ 08553.

2) VEGF packaged into 21 day release pellets were obtained from Innovative Research of America, using patented matrix driven delivery system. Pellets  
10 were packaged at 0.20, 0.21, or 2.1  $\mu$ g VEGF/pellet. These doses approximate 10 and 100 ng/day release of VEGF. (Innovative Research of America, 3361 Executive Parkway, P.O. box 2746, Toledo, Ohio 43606)

3) Methylcellulose  
15 4) Water (sterile)  
5) Methanol  
6) Appropriate drugs/inhibitors  
7) 10 cm culture plates  
8) parafilm

20 The following protocol was then followed to conduct the VEGF pellet model:

1) VEGF, purchased from Peprotech, was sent to Innovative Research for Custom Pellet preparation;

25 2) Methylcellulose prepared at 1.5% (w/v) in sterile water;

3) Drugs solubilized in methanol (usual concentration range = 10 to 20 mg/ml);

4) Place sterile parafilm in sterile 10 cm plates;

30 5) 150  $\mu$ l of drug in methanol added to 1.35 ml of 1.5% methylcellulose and mixed/vortexed thoroughly;

6) 25  $\mu$ l aliquots of homogenate placed on parafilm and dried into discs;

35 7) Mice (6-10 wk. Balb/C athymic nu/nu, female) were anesthetized via isoflurane inhalation;

8) VEGF pellets and methylcellulose discs were implanted subcutaneously on the abdomen; and

9) Mice were scored at 24 hours and 48 hours for reddening and swelling response.

The specific experimental design used in this example was:

5

N = 4 animals/group

Controls: VEGF pellet + drug placebo

VEGF placebo + drug pellet

10 **Experimental Results.** The compounds of the present invention are expected to demonstrate activity according to this assay.

#### 6.4.3. Mammary Fat Pad Model

Because of the established role played by many of the RTKs, e.g., the HER2 receptor, in breast cancer, the mammary fat pad model is particularly useful for measuring the efficacy of compounds which inhibit such RTKs. By implanting tumor cells directly into the location of interest, *in situ* models more accurately reflect the biology of tumor development than do subcutaneous models. Human mammary cell lines, including MCF-7, have been grown in the mammary fat pad of athymic mice. Shafie and Grantham, 1981, *Natl. Cancer Instit.* 67:51-56; Gottardis et al., 1988, *J. Steroid Biochem.* 30:311-314. More specifically, the following procedure can be used to measure the inhibitory effect of a compound on the HER2 receptor:

25

1) Implant, at various concentrations, MDA-MB-231 and MOF-7 cells transfected with HER-2 into the axillary mammary fat pads of female athymic mice;

30

2) Administer the compound; and

3) Measure the tumor growth at various time points.

35 The tumors can also be analyzed for the presence of a receptor such as HER2, by Western and



immunohistochemical analyses. Using techniques known in the art, one skilled in the art can vary the above procedures, for example through the use of different treatment regimes.

5       The present invention is not to be limited in scope by the exemplified embodiments which are intended as illustrations of single aspects of the invention, and any clones, DNA or amino acid sequences which are functionally equivalent are within the scope of the invention. Indeed, various modifications of  
10       the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the  
15       scope of the appended claims.

      All references cited herein are hereby incorporated by reference in their entirety.

20

25


30

35

CLAIMS

What Is Claimed:

1. A compound having the formula:



10 and pharmaceutically acceptable salts, thereof,  
wherein:

X is O or S;

Q is an aryl (either mono- or bicyclic)  
optionally substituted with one or more R²;

15 n is 1, 2, 3 or 4;

R¹ is cyano, NO₂, C(O)NHR², S(O)₂R² or S(O)₂NHR²;

and

R² is H, halo, trihalomethyl, alkyl, thioalkyl,  
20 hydroxy, alkoxy, nitro, cyano, sulfonyl, amide,  
carboxyl, sulfonamide or amino.

2. The compound of Claim 1 wherein said  
compound has the formula



30 and pharmaceutically acceptable salts thereof, wherein  
R₂ and Q are as follows:


35

R₂	Q
6,8-dichloro	4-fluorophenyl
8-methoxy	4-fluorophenyl

	6-chloro	2,4-dichlorophenyl
	6-chloro	4-(methylmercapto)phenyl
	6-chloro	4-(methylmercapto)phenyl
	6-chloro	4-phenoxyphenyl
5	H	4-isopropylphenyl
	benzo	4-chlorophenyl
	H	thien-2-yl
	H	2-methoxyphenyl
	6-bromo	2-methoxyphenyl
	H	benzofuran-2-yl
10	6-chloro	2-cyanophenyl
	8-methoxy	2-nitrothien-4-yl
	8-methoxy	4-hydroxy-3-methoxyphenyl
	8-methoxy	1-phenylpyrazol-3-yl
	8-methoxy	1-methylpyrazol-3-yl
15	8-methoxy	5-bromo-2-methoxyphenyl
	8-methoxy	4-cyanophenyl
	8-methoxy	thien-3-yl
	8-methoxy	3-(trifluoromethyl)phenyl
	8-methoxy	thien-2-yl
20	6,8-dichloro	2-hydroxy-3-methoxy
	6,8-dichloro	4-chloro-1-methylpyrazol-3-yl
	6,8-dichloro	3-bromothien-5-yl
	6,8-dichloro	2,5-dimethoxyphenyl
25	6,8-dichloro	4-t-butylphenyl
	6,8-dichloro	4-acetamidophenyl
	6,8-dichloro	dioxolo[2,3-c]phenyl

3. A pharmaceutical composition comprising a  
 30 compound having the formula:

35



5

and pharmaceutically acceptable salts, thereof,  
wherein:

- 10 X is O or S;  
Q is an aryl (either mono- or bicyclic)  
optionally substituted with one or more R<sup>2</sup>;  
n is 1, 2, 3 or 4;  
R<sup>1</sup> is cyano, NO<sub>2</sub>, C(O)NHR<sup>2</sup>, S(O)<sub>2</sub>R<sup>2</sup> or S(O)<sub>2</sub>NHR<sup>2</sup>;  
15 and  
R<sup>2</sup> is H, halo, trihalomethyl, alkyl, thioalkyl,  
hydroxy, alkoxy, nitro, cyano, sulfonyl, amide,  
carboxyl, sulfonamide or amino; and  
and a pharmaceutically acceptable carrier or  
excipient.

20 4. A method for treating diseases related to  
cell proliferative disorders comprising administration  
of an effective amount of the composition of Claim 3.

5. A method of Claim 4 wherein said disease is  
25 selected from the group comprising cancer, blood  
vessel proliferative disorders, fibrotic disorders,  
mesangial cell proliferative disorders and metabolic  
diseases.

6. The method of Claim 5 wherein the cancer is  
30 related to tyrosine kinase signal transduction.

7. The method of Claim 5 wherein the blood  
vessel proliferative disorder is selected from the  
group comprising cancer, arthritis, restenosis.

8. The method of Claim 5 wherein the fibrotic  
35 disorder is selected from the group comprising hepatic  
cirrhosis and atherosclerosis.

9. The method of Claim 5 wherein the mesangial cell proliferative disorder is selected from the group comprising glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, transplant rejection and glomerulopathies.

5 10. A method for of Claim 5 wherein the metabolic disorder is selected from the group comprising psoriasis, diabetes mellitus, wound healing, inflammation and neurodegenerative diseases.

10 11. A method for regulating, inhibiting or modulating tyrosine kinase transduction comprising administration of an effective amount of the composition of Claim 3.

15

20

25

30

35

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/08312

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 31/35, 31/38, 31/415; C07D 311/60, 335/06, 403/04  
US CL : 514/406, 432, 456; 548/364.4; 549/23, 403, 404, 405, 406, 407, 408, 409, 410  
According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/406, 432, 456; 548/364.4; 549/23, 403, 404, 405, 406, 407, 408, 409, 410

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN CAS ONLINE, APS (SUBCLASSES, CELL PROLIFERAT?, PHARMACEUT?, CANCER)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4,665,202 A (C.G. RIMBAULT ET AL.) 12 May 1987 (12.05.87), column 1, lines 12-43.	1-5, 8, 10
X	Chem. abstr., Vol. 84, No. 3, 19 January 1976 (Columbus, OH, USA) page 441, column 2, the abstract No. 17075k, RENE et al., 'Synthesis of 3-chromenes with electron-attracting substituents as pharmacological benzofuran analogs.' Eur. J. Med. Chem.-Chim. Ther. 1975, 10(1), 72-78 (FR). Registry Numbers 57544-14-6, 57544-22-6, see entire abstract and registry numbers.	1-3
X	Chem. abstr., Vol. 108, No. 19, 09 May 1988 (Columbus, OH, USA) page 589, column 1, the abstract No. 166840x, MITCHELL et al., 'Mass spectra of 3-nitro-2H-chromenes and 3-nitrochromans.' J. Chem. Soc. Perkin Trans. 2. 1987, (10) 1495-1498 (Eng), see entire abstract.	1-3

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Z" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

24 JULY 1996

Date of mailing of the international search report

23 AUG 1996

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

LAURA L. STOCKTON

Telephone No. (703) 308-1235

Form PCT/ISA/210 (second sheet)(July 1992)\*

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/08312

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Chem. abstr., Vol. 122, No. 25, June 1995, (Columbus. OH, USA) page 929, column 2, the abstract no. 314454f, ONO et al., 'Preparation of nitrochromene derivatives as nonlinear optical materials.' JP 07-70,104 (MITSUBISHI KAGAKU KK) 14 March 1995, see entire abstract.	1-3
X	Chem. abstr., Vol. 99, No. 9, 29 August 1983 (Columbus. OH, USA) page 609, column 1, the abstract No. 70526u, DESHPANDE et al., 'Synthesis of 2-aryl-3-nitrochromenes.' Indian J. Chem., Section B. 1983, 22B(2), 166-167 (Eng), see entire abstract.	1-3

Form PCT/ISA/210 (continuation of second sheet)(July 1992)\*